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PURPOSE The purpose of this investigation was to improve understanding of the cardiovascular 
health and aerobic capacity profile of breast cancer survivors (BCS) and the role of community-
based exercise to impact these profiles during early cancer survivorship. PARTICIPANTS Thirty-
five early stage BCS who were within one year of completing either chemotherapy and/or radiation 
and twenty-one age-matched, sedentary, non-cancer controls (CTL) were enrolled for this study. 
METHODS: Applanation tonometry and cuff-based techniques were used to measure arterial 
stiffness (pulse wave velocity, augmentation index) and central hemodynamics (blood pressure, 
Buckberg Index). Cardiopulmonary exercise testing (CPET) on a cycle ergometer was used to 
evaluate aerobic capacity (VO2peak) before and after aerobic and strength exercise training 3 days 
per week for 16-weeks at a community-based training center. Linear mixed models were used to 
evaluate arterial stiffness and aerobic capacity between groups before and after exercise training. 
Exploratory univariate analyses investigated relationships between changes in arterial stiffness and 
aerobic capacity, respectively, with measures of exercise engagement. RESULTS Arterial stiffness 
between BCS and CTLs reflected that of healthy normal values at baseline and did not change 
following exercise. However, exploratory analyses of only BCS revealed significant increase in 
arterial stiffness regardless primary cancer treatment. Days of aerobic compliance were associated 
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(R= -0.343, p=0.038) with pre-post change in PWV in a pooled sample. Aerobic capacity 
(1.2mL/kg/min; 95% CI [0.15, 2.27]; p=0.03) improved equitably between groups following 
training. Both groups attended 71% of prescribed days. Aerobic compliance was 54% for BCS, 
67% for CTL and strength compliance was 29% for BCS and 38% for CTL. CONCLUSION 
Community-based exercise appears to be a promising route for cancer survivors to improve aerobic 
capacity, but more studies evaluating vascular health in BCS are needed to better understand our 
preliminary findings. Efforts to improve exercise compliance in community-based settings may 
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In 2019 alone, over a quarter of a million women will be diagnosed with breast cancer – 
the most common cancer diagnosis for women in the United States (Cancer Statistics Center, 
2018). Decades of work devoted to improving cancer detection, identifying tumors at earlier 
stages, and advancing treatment technologies have resulted in favorable long-term prognoses for 
thousands of BCS (Miller et al., 2016). However, the advancements are bittersweet. While breast 
cancer therapies are powerful tools for fighting tumors, they can also induce a number of life-
changing negative side effects including but not limited to peripheral neuropathy, sleep 
disturbances, loss of strength and endurance, increased fatigue, and decreased functionality that 
warrant extra care or threaten treatment completion (Kirsten A Nyrop et al., 2018; Schmitz, 
DiSipio, Gordon, & Hayes, 2015). As the BCS survivor pool continues to grow into the millions, 
managing the volume of survivors with debilitating side effects becomes a personal and public 
health challenge (Bluethmann, Mariotto, & Rowland, 2016).  In particular, cardiovascular 
complications and increased risk of cardiovascular events in BCS is of particular concern 
(Armenian et al., 2017; Patnaik, Byers, DiGuiseppi, Dabelea, & Denberg, 2011). Unfortunately, it 
has been realized that as BCS age, risk of dying from cardiovascular complications exceeds that 
of their cancer (Patnaik et al., 2011). The impact is so severe that a specialization termed “cardio-
oncology” has developed and first-ever breast cancer/cardiac risk position statements have been 
made by the American Heart Association (Mehta et al., 2018).  
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Research has demonstrated that lifestyle risk factors at diagnosis from physical inactivity 
and/or poor dietary habits in concert with toxic cancer therapies is a particularly dangerous 
combination for long-term cardiovascular health in the breast cancer population (L. W. Jones, 
Haykowsky, Swartz, Douglas, & Mackey, 2007). The loss of cardiovascular health/function 
related to cancer and treatments in BCS is also characterized by exercise intolerance and an 
attenuated maximal capacity to uptake and utilize oxygen (“aerobic capacity”) (L. W. Jones, 
Courneya, et al., 2012). Aerobic capacity is the gold standard measure for cardiopulmonary fitness, 
and reflects an individual’s integration of cardiac and vascular systems/structures in the body. Loss 
of aerobic capacity can have a direct impact on patient quality and quantity of life, and impairments 
warrant specific attention for individual well-being (L. W. Jones, Haykowsky, Pituskin, et al., 
2007a; Kaminsky et al., 2013).  Lower aerobic capacities have been associated with increased 
mortality, both cancer and non-cancer specific, increased morbidity, and less favorable patient 
outcomes (J. B. Peel et al., 2009). Associations between low aerobic capacity and increased 
mortality following surgery have been observed in specific cancer populations. Unfortunately, 
aerobic capacities also diminish throughout the cancer continuum, especially during adjuvant 
therapy, but exercise can provide powerful leverage to improve aerobic capacity in the adjuvant 
setting (L. W. Jones et al., 2016; Lakoski et al., 2013; Lakoski, Jones, Krone, Stein, & Scott, 2015; 
J. B. Peel et al., 2009; J M Scott et al., 2018).  
As a quantification of whole-body oxygen consumption, aerobic capacities reflect cardiac 
and vascular integration, and reduced values in BCS suggest impairments related to the organ 
structures/systems responsible for oxygen uptake, distribution, and utilization (L. W. Jones, 
Haykowsky, Swartz, et al., 2007; Jessica M Scott, Nilsen, Gupta, & Jones, 2018). Cardiac-specific 
damage in BCS has been well-studied, but vascular or peripheral (microvascular, muscular) 
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damage has not received the same attention. However, due to the integration and dependency 
between cardiac, vascular, and muscular structures of the body, a combination of insults likely 
contributes to the overall decreased aerobic capacity and increased cardiovascular disease risk 
observed in BCS. Chemotherapies and targeted therapies, such as anthracyclines and trastuzumab, 
have known detrimental effects on the cardiac system and developing evidence supports the 
vascular system may be insulted as well (Jain, Russell, Schwartz, Panjrath, & Aronow, 2017; 
Mulrooney, Blaes, & Duprez, 2012). It is also possible that a “domino effect” exists: observed 
cardiac damage in BCS may be downstream from cancer therapy-induced vascular damage, and/or 
compromised conduit vascular function may impair peripheral microvascular function. The overall 
effect may be represented by a decreased systemic aerobic capacity and increased susceptibility to 
future cardiovascular events. However, more work is needed to elucidate the cardiovascular 
profiles of BCS following treatment and the relationship of these individual systems to overall 
aerobic capacity. Clarifying the specific cardiovascular components potentially affected by cancer 
and cancer therapies, how they relate to overall aerobic capacity, and the potential ability to protect 
or recover their health and function with targeted interventions would provide important advances 
for the field of cardio-oncology. 
Exercise therapy is a well-established method to improve systemic aerobic capacity and 
certain specific cardiovascular outcomes, and is a standard of care in cardiac-specific rehabilitation 
for heart failure patients (L. W. Jones et al., 2008). Aerobic exercise has also been shown to 
improve arterial stiffness (Ashor, Lara, Siervo, Celis-Morales, & Mathers, 2014). However, the 
impact of exercise on specific cardiac and vascular outcomes including those related to arterial 
stiffness and/or peripheral components of the oxygen cascade, has received minimal attention in 
BCS (Mulrooney et al., 2012). Exercise has been proven a safe and feasible option to significantly 
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improve cardiorespiratory fitness in BCS but prescriptions have yet to be optimized and survivors 
still exhibit cardiovascular challenges and fatal future cardiovascular events (Battaglini et al., 
2014a; Kearney et al., 2017; Lakoski, Eves, Douglas, & Jones, 2012; McNeely et al., 2006). 
Additionally, no standardized practice exists to monitor cardiovascular health long-term in BCS, 
and potential sensitive, diagnostic approaches like cardiac MRI are expensive and logistically 
challenging (Armenian et al., 2017). More clinically feasible options such as non-invasive 
oscillometric or tonometric techniques that could be employed consistently would be highly 
beneficial. In the meantime, clinicians caring for BCS are encouraged to remain acutely aware of 
potential cardiac complications and quickly evaluate patients who appear symptomatic (Armenian 
et al., 2017). To maximize effective, patient-centered care, there is an increasing need to identify 
specific cardiovascular vulnerabilities in breast cancer survivors and to determine feasible and 
appropriate interventions capable of improving components and overall cardiovascular 
performance. Exercise may be a powerful solution but more work is needed to evaluate the impact 
of training on individual cardiovascular components and their overall impact on aerobic capacity 
(Jessica M Scott et al., 2018). In the scope of long-term cancer care, as the number of cancer 
survivors continues to grow, the need to accommodate large volumes of people with effective 
interventions becomes essential, yet challenging, and community-based interventions may be 
necessary (Bluethmann et al., 2016). Lastly, the ability to identify at baseline which types of 
patients would benefit from which types of interventions would dramatically improve our ability 
to streamline patient-centered care and maximize individual outcomes, and should therefore 
remain a priority in the field. 
 5 
Statement of Purpose 
 Cardiovascular disease mortality is a global burden and a particular threat to BCS due to 
potential cardiac and vascular specific damage from cytotoxic cancer therapies. There is a critical 
need to evaluate cancer therapy-induced cardiovascular damage in BCS which may be an 
important contributor to the observed increased cardiovascular risk and decreased aerobic 
capacity in this population. Furthermore, determining interventions that may improve or protect 
vulnerable cardiovascular organs/systems will provide patients with means to enhance long-term 
well-being.  
Therefore, the purpose of this study was to compare the cardiovascular and aerobic 
capacity profiles of BCS who have recently completed primary cancer treatments with otherwise 
healthy, non-cancer controls (CTL) before and after a 16-week, community-based exercise 
program. Exploratory analyses investigated the utility of baseline cardiovascular measures as 
predictors of exercise response (quantified by deltaVO2peak), and also investigated the 
relationship between baseline p16INK4a, a marker of molecular aging, and important measures of 
clinically and functionally measures of patient outcomes.  
This study enhanced our understanding of cardiovascular system outcomes following 
cancer therapies and in response to community-based exercise training stimuli. These efforts can 
help lay the foundation for future studies to consider implementing cardio- and vaso-specific 
protective strategies before or during cancer therapy, and to help maintain and/or improve long-
term cardiovascular outcomes of the largest group of cancer survivors in the nation. 
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Definition of Terms and Abbreviations 
Aerobic capacity: The ability of the body to uptake, distribute, and utilize oxygen in the body 
and is quantified in this study as VO2peak (mL O2 /kg/min). 
 
Breast Cancer Survivors (BCS): Woman with a confirmed breast cancer diagnosis and includes 
all phases of the cancer continuum from diagnosis to treatment to decades following treatment 
completion living with a history of cancer. In this study, BCS were early stage (0-III) survivors 
who were within one year of completing their primary breast cancer treatments (surgery, 
chemotherapy, radiation). 
 
Otherwise healthy, non-cancer controls (CTL): Women ≥21 years old without any cancer 
diagnosis/history or other overt, known health concerns and who exercise two or fewer days per 
week at enrollment. 
 
VO2peak: peak quantity (mL O2/kg/min) of oxygen consumed during a cardiopulmonary exercise 
test (CPET) on a cycle ergometer. VO2peak was calculated as the average of the three highest, 
five-second averages of recorded oxygen consumption measures during the last minute of a 
CPET. 
 
Oxygen Cascade: The stepwise flow/movement of oxygen in the body from 
inhalation/pulmonary diffusion, delivery by the heart, transport by conduit vasculature, and 
consumption across microvasculature at the peripheral working tissue (in this study, muscles) 
(Hoppeler & Weibel, 1998).  
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Cardiovascular profile/components: Measures of cardiac and vascular health outcomes including 
arterial stiffness (quantified by pulse wave velocity (PWV)), augmentation index (AIx), and 
Buckberg Index obtained via non-invasive tonometry methods (PWV, AIx, Buckberg).  
 
Community-based exercise program: Refers to the University of North Carolina Get REAL & 
Heel (GRH) Breast Cancer exercise rehabilitation program for cancer survivors. This is a 3-day 
per week, supervised group exercise program specifically designed for breast cancer patients and 
includes both aerobic and strength training customized to each patient’s ability. 
 
p16INK4a: Tumor suppressor protein that has been evaluated as a biomarker of molecular aging in 
peripheral T-cells collected from standard venipuncture  
 
Research Aims and Hypotheses 
 The purpose of this investigation was addressed by two primary aims illustrated in Figure 
1. Aim #1 evaluated the cardiovascular profile, primarily arterial stiffness (PWV), of BCS 
compared to CTL before and after 16-weeks of community-based exercise training. This Aim is 
addressed in Manuscript One. Aim #2 evaluated cardiorespiratory fitness, specifically aerobic 
capacity (VO2peak), of BCS compared to CTL before and after 16-weeks of community-based 
exercise training. This Aim is addressed in Manuscript Two. 
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Figure 1. Conceptual model leading to research aims.  
 
Primary and Secondary Aims 
 
Aim 1: To determine the cardiovascular profile of breast cancer survivors compared to women 
without a cancer history before and after a 16-week, community-based exercise program. 
Null Hypothesis 1a: PWV will not differ between BCS and CTL at baseline. 
Null Hypothesis 1b: Changes in PWV will not differ between BCS and CTL following 
participation in community based, exercise training. 
Aim 2: To determine cardiorespiratory fitness of breast cancer survivors compared to women 
without a cancer history before and after a 16-week, community-based exercise program. 
Null Hypothesis 2a: VO2peak will not differ between BCS and CTL at baseline. 
Null Hypothesis 2b: Changes in VO2peak will differ between BCS and CTL following 
participation in community based, exercise training. 
Exploratory Analyses 
In addition to the previously stated Research Aims, three exploratory analyses were also 
conducted. The first exploratory analysis evaluated the relationship between baseline 
cardiovascular variables (PWV, AIx, Buckberg Index) with changes in cardiorespiratory fitness 
(DVO2peak) in BCS and CTL. A second exploratory analysis evaluated the relationship between 
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baseline cardiovascular variables (PWV, AIx, Buckberg Index) with training response 
(responders (DVO2peak ≥ 2.5ml/kg/min) vs. non-responders (DVO2peak < 2.5ml/kg/min)) in BCS 
and CTL.  A third exploratory analysis evaluated the relationship between baseline p16INK4a 
biomarker of aging and clinical/functional patient outcomes including but not limited to 
DVO2peak, arterial stiffness, 6MWT, and lean body mass. 
 
Assumptions 
1. All of the participants followed the pre-test and post-test guidelines. 
2. All of the participants were honest in answering questions related to medical history and 
physical activity.  
3. All participants honestly engaged in exercise at the community-based facility to the best 
of their abilities. 
4. All participants maintained current/normal lifestyles (nutrition, other physical activity) 
throughout the 16-week study period with the exception of the exercise intervention 
prescribed by researchers. 
5. All participants remained under routine cancer care and long-term therapy (endocrine 
treatment), as appropriate, and immediately communicate any pertinent health related 
changes (especially oncologic or cardiovascular related changes) with the research team. 
Limitations 
1. Baseline evaluation of BCS in this study were completed after primary cancer therapies. 
Therefore, cardiovascular outcomes pertinent to this study prior to cancer therapy is 
unknown, subsequently, the changes in outcomes specifically due to cancer therapies 
cannot be determined but may be speculated with descriptive statistics. 
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2. Exercise intervention intensity was primarily evaluated using subjective, patient reported 
exertion (using Borg rating of perceived exertion (RPE) scale) which may be less specific 
than heart rates or oxygen uptake but is a necessary design for realistic and practical 
implementation in a community-based, non-randomized controlled design. 
3. Negative impacts (both objective and subjective) of long-term cancer related medications 
(ex: endocrine therapy) may become enhanced over the study duration, however this is 
standard of cancer care and were accommodated as best as possible during the study. 
Delimitations 
1. A relatively select sample size of locally-residing women due to need to attend exercise 
sessions at Get REAL & Heel 3 days per week for 16 weeks. 
2. Only women who had completed their major breast cancer anti-cancer treatments within 
the past year were eligible to participate in the study. 
3. Only women who were not currently participating in regular exercise defined as 
physically active no more than 2 days per week. 
Significance 
The damaging effects of certain breast cancer therapies on cardiovascular health in 
combination with existing risk factors places breast cancer patients at particular risk for developing 
cardiovascular disease (L. W. Jones, Haykowsky, Swartz, et al., 2007). Determining, monitoring, 
and detecting vulnerable components, affected structures, and clinically relevant deterioration, 
respectively, is essential for patient quality and quantity of life (Armenian et al., 2017). 
Implementing and evaluating feasible interventions with cardioprotective potential would enhance 
our ability to optimally care for cancer patients. As the cancer survivor pool continues to grow, 
these challenges are both critical and necessary (Bluethmann et al., 2016).  
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This project aimed to enhance our understanding of the cardiovascular status of BCS who 
have completed primary cancer therapies compared to women without a cancer history, and the 
impact of community-based exercise training on their cardiovascular profiles. This study helped 
maximize the opportunity for patient-centered cancer care by evaluating novel and vital 
cardiovascular-specific outcomes currently lacking in the literature, and is an important step 







CHAPTER TWO: LITERATURE REVIEW 
 
Overview 
For the purpose of organization, this review of literature is divided into four main sections. 
The first section provides an overview of breast cancer and associated side effects of treatment. 
The second section reviews specific cardiovascular toxicities of breast cancer therapies. The third 
section will discuss cardiorespiratory fitness based on the oxygen cascade and cardiovascular 
hemodynamics. The fourth section will focuses on the potential benefit of exercise training in the 
oncology setting for improving cardiovascular physiology, function, and performance. 
Section I: Breast Cancer 
Breast cancer is the most common malignancy in women; affecting approximately 2.7 
million globally each year, and killing approximately one woman per minute per day (Patnaik et 
al., 2011) The financial footprint of breast cancer is substantial and approximates ~4% of the Gross 
Domestic Product, roughly 620-740 billion dollars (Bigby & Holmes, 2005). Fortunately, 
improved early detection, precise medical technologies, better treatment strategies, and robust 
cancer therapies have resulted in a relatively controlled incidence of breast cancer and a growing 
pool of survivors (approximately 3.1 million in the U.S. as of 2016) (Bluethmann et al., 2016; 
Miller et al., 2016; Runowicz et al., 2016; Siegel, Miller, & Jemal, 2015). Surgery, chemotherapy, 
and radiation cancer therapies have changed over the years to provide more precise, powerful, and 
effective treatment for breast cancer. However, these same therapies that have successfully 
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improved disease-free survival (DFS) and overall survival (OS) for breast cancer patients also 
place healthy cells at risk for damage.  
Side Effects of Breast Cancer Treatment 
While tumor cells are the primary target for cancer therapies, chemotherapy, for example, 
is toxic to rapidly dividing cells - a defining feature of cancer (Hanahan & Weinberg, 2000). 
However, other non-cancerous cells in the body, like those of the gastro-intestinal tract, hair, and 
skin, are also rapidly dividing. Chemotherapy-induced damage to these otherwise healthy cells can 
result in undesired and potentially debilitating side effects like nausea, vomiting, neutropenia, 
thrombocytopenia, fatigue, and paresthesia, among others. If side effects become too severe, 
cancer therapy can be delayed, require dose reductions, or even be discontinued based on patient 
recovery response. While a treatment hiatus provides opportunity for patient rebound from 
negative side effects, a discontinuous regimen may compromise the efficacy of the established 
benefits of therapy (Hershman et al., 2011).  Side effects, both long and short term, can 
significantly impact a patient’s quality and quantity of life (Basch et al., 2017; K.A. Nyrop et al., 
2018).  
Symptoms from chemotherapy treatment can improve with time following cessation of 
therapy, however, potentially permanent and severe side effects are possible. The most well-
documented, severe, and permanent side effect of breast cancer treatment is congestive heart 
failure as a result of the most commonly used class of chemotherapy; anthracyclines (Armenian et 
al., 2017; Floyd et al., 2005). This life-altering condition is obviously highly concerning and recent 
growing attention to critical cardiovascular issues in cancer survivors has resulted in the emergence 
of the ‘cardio-oncology’ subspecialty in medical institutions (Jain et al., 2017). It is becoming 
increasingly evident that BCS (especially older individuals) can actually be at a higher risk of 
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dying from CVD than breast cancer, likely due to the ‘multiple hit’ of poor lifestyle habits, 
cardiotoxic cancer therapies, and overall autonomic dysfunction (Gernaat et al., 2017; L. W. Jones, 
Haykowsky, Pituskin, et al., 2007b; Lakoski et al., 2015; Patnaik et al., 2011; J M Scott et al., 
2018; Shiovitz & Korde, 2015). Additionally, damage to the cardiovascular system can 
compromise independence and impair functional capacities potentially altering quality of life (K 
S Courneya et al., 2003; Paterson, Cunningham, Koval, & St Croix, 1999). Especially as the 
numbers of BCS grow, efforts to prevent, attenuate, and reverse cardiotoxic consequences of 
cancer treatments are warranted and necessary (Armenian et al., 2017; Schmitz, Prosnitz, 
Schwartz, & Carver, 2012).  
Section II: Cardiovascular Toxicity of Breast Cancer Therapy 
The impact of cancer therapies on the components of the cardiovascular system, the 
associated effects on the ability to uptake, distribute, and consume oxygen in the body, and the 
long-term implications of cardiovascular health is a topic of tremendous interest in the medical 
community. Soundly functioning cardiac and vascular systems are essential for oxygen utilization 
in the body, and can be quantified as aerobic capacity (measured as VO2). Breast cancer survivors 
have demonstrated significant impairments (10-30% decrement) in aerobic capacities across the 
cancer care continuum which suggests disruption in cardiac and/or vascular systems (Jones, 
Courneya, et al., 2012). Loss of aerobic capacity is particularly concerning because impairments 
have been significantly associated with increased mortality, worse symptom burden, increased 
treatment toxicity, and decreased overall quality of life in cancer patients (K S Courneya et al., 
2003; Kerry S Courneya et al., 2014; Herrero et al., 2006; L. W. Jones, Hornsby, et al., 2012). Due 
to the unique impact therapies may have on the cardiac versus vascular structures, these two 
systems will be addressed independently below per primary therapy. More is known about cardiac 
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specific damage than vascular specific damage but natural and physical linkage between the 
cardiac and vascular system, the nature of cancer therapy administration via intravenous infusion 
(chemotherapy) and/or central vessel exposure during radiation suggests that the vascular system 
may be particularly vulnerable to toxic effects of cancer therapies. Evidence suggesting prevalence 
of vascular injury is increasing and vascular damage from cancer therapy may be a unique 
contributor to cardiovascular disease risk, may develop independently from cardiac-specific 
damage, and/or may enhance cardiac specific dysfunction in breast cancer populations (Blaes et 
al., 2017; L M Jones, Stoner, Brown, Baldi, & McLaren, 2013; Koelwyn et al., 2016; J M Scott, 
Adams, Koelwyn, & Jones, 2016). Therefore, more attention to understand the impact of primary 
cancer therapies on both cardiac and vascular structures and their ability to support oxygen 
utilization in the body is extremely warranted. 
Surgery 
 
Surgery is a local, site-specific therapy for breast cancer designed to physically remove the 
tumor from the body. In early stage breast cancers, surgery usually occurs before chemotherapy 
but may occur after, depending on the tumor size and adjuvant treatment intention. Tissue samples 
removed from the tumor during surgery can be used to determine tumor stage, grade and help 
clarify overall prognosis. The decision for surgery and volume of tumor and breast tissue removed 
depend on the specific tumor size, location, prognosis, and patient cosmetic desire. A radical 
mastectomy involves removal of the entire affected breast and is usually performed when the 
tumor is diffuse or particularly aggressive, or simply by patient desire. Breast conserving therapy 
(BCT), which includes a lumpectomy plus radiation, is the primary treatment strategy for early 
stage breast cancer. Lumpectomies remove only the tumor and a margin of normal breast tissue 
surrounding the tumor while leaving the majority of the breast intact. Breast surgeries are usually 
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accompanied by lymph node dissection, either sentinel or axillary, that help oncologists determine 
the likelihood that the tumor has spread to other parts of the body. Sentinel nodes are located close 
to the breast and are the most likely nodes to contain rogue cancer cells. If evidence of cancer cells 
exists in the sentinel nodes, a surgeon may complete an axillary lymph node dissection. These 
additional lymph nodes located peripheral to the breast are removed and help indicate the 
likelihood of metastasis to the body (Galimberti et al., 2013). 
In terms of cardiovascular risks, breast cancer surgery alone has not been associated with 
long-term cardiovascular disease development. 
Chemotherapy 
Perhaps the most critical yet challenging goal of cancer treatment is preventing tumor 
progression and minimizing metastatic potential. Chemotherapy, targeted therapy, and hormonal 
therapies circulate the whole body to target rogue cancer cells that may have metastatic potential. 
Chemotherapy, given intravenously or by pill, has proven tremendously successful in preventing 
recurrence and promoting cancer-specific survival, and is a cornerstone treatment in our arsenal of 
cancer therapies (Mansour et al., 1989, 1998; Peto et al., 2012). Targeted therapy and hormonal 
therapy are systemic treatments with use dependent on tumor cell membrane receptor expression 
characteristics (D. Slamon et al., 2011).  
Common classes of chemotherapies include but are not limited to: anthracyclines, 
antimetabolites, antimicrotubular agents, and tyrosine kinase inhibitors that destroy cancer cells 
through a variety of mechanisms (Gradishar et al., 2018). The diversity in mechanisms of action 
(MOA) between different chemotherapies provides beneficial alternatives for cancer treatment in 
the event patients are not able to tolerate a particular regimen. Anthracyclines are a legacy drug 
for cancer treatment and are considered an essential medicine by the World Health Organization 
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(WHO) (“19th WHO Model List of Essential Medicines (April 2015),” 2015). These foundational 
drugs are the most widely used chemotherapies for systemic treatment of breast cancer, used in 
over one-third of breast cancer patients (Giordano, Lin, Kuo, Hortobagyi, & Goodwin, 2012; 
Mulrooney et al., 2012). Mechanistically, anthracycline agents intercalate between base pairs of 
DNA and RNA, interfere with critical DNA replication enzymes, and induce substantial oxidative 
damage resulting in tumor cell death (Jain et al., 2017). Common chemotherapy routines including 
anthracyclines involve four to six cycles of therapy occurring in a two or three-week frequency 
with drugs given individually or in combination, depending on the regimen selected by the treating 
oncologist (Gradishar et al., 2018).  
Cardiotoxicity of Anthracycline Chemotherapy 
 
Chemotherapy-induced cardiotoxicity from anthracycline therapy is well documented in 
the literature (Floyd et al., 2005; Jain et al., 2017). First identified in the 1970’s, anthracycline-
induced cardiotoxicity is dose-dependent with incidence ranging from 3%-48%, based on the 
cumulative dose received. This discovery led to the development of guidelines limiting a patient’s 
cumulative lifetime dose of anthracyclines to approximately 500mg/m2 (Von Hoff et al., 1979). 
However, cardiotoxicity can occur at doses below this threshold and nevertheless, constrains 
treatment efficacy (Swain, Whaley, & Ewer, 2003; Von Hoff et al., 1979).  
Symptomatic anthracycline-induced cardiotoxicity can be acute (within days), early-onset 
(within the first year of drug administration), or late-onset (greater than one year from drug 
administration) and is the most severe clinical concern of cancer treatment (Henriksen, 2018). 
Acute toxicity is the least concerning, usually resulting in transient cardiac rhythm changes, but 
also somewhat uncommon. Early and late onset cardiomyopathies are initially quantified by 
declines in left ventricular ejection fraction (LVEF) and can progress irreversibly to congestive 
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heart failure (CHF), or may become clinically detectable only after permanent damage has 
occurred (Doyle, Neugut, Jacobson, Grann, & Hershman, 2005; Lakoski et al., 2015; Von Hoff et 
al., 1979). With a hazard ratio of 3.46 compared to , this specific heart failure imparts an especially 
poor prognosis for breast cancer patients (Felker et al., 2000). In the absence of standard long-term 
cardiac-specific follow up practices for cancer patients, effective monitoring of potential 
cardiotoxicity is logistically challenging (Schmitz et al., 2012). In attempt to capture and treat 
potential cardiotoxicity as early as possible, a recent review suggested that suspicion for 
cardiotoxicity in cancer survivors should remain high and standards for evaluation be low 
(Armenian et al., 2017). Other groups have suggested cardiovascular-specific evaluations be 
completed in all patients starting adjuvant treatment, regardless the specific therapy (Koelwyn, 
Khouri, Mackey, Douglas, & Jones, 2012). Needless to say, developing improved strategies to 
identify patients at high cardiovascular disease risk and implementing cardio-protective 
approaches to cancer care is highly warranted. 
Development of alternative anthracycline analogs with decreased cardiotoxic threat has 
been attempted but with minimal success (McGowan et al., 2017; Weiss, 1992). However, current 
research suggests there has been a steady decline in anthracycline use from 2005 until present and 
taxane-based regimens appear to be slowly replacing anthracyclines (Giordano et al., 2012). 
Furthermore, recent findings suggest most women at moderate risk of breast cancer recurrence do 
not necessarily benefit from chemotherapy, and may therefore no longer warrant receipt of the 
treatment (Sparano et al., 2018). However, use of cardiotoxic therapies has not ended entirely and 
extended adjuvant treatment regimens are being used in clinical practice; increasing potentially 
toxic exposure duration.  Furthermore, the volume of survivors previously treated with known 
cardiotoxic agents will still require attention. This is especially important as the demand to care 
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for the growing number of survivors may outpace the medical providers available to serve 
(Bluethmann et al., 2016). Efforts to clarify the mechanisms responsible for cardiovascular damage 
and toxicity will enhance the ability to design and implement cardioprotective strategies. 
No single mechanism has been identified as the predominant contributor to anthracycline-
induced cardiotoxicity, and the process is indeed complex. It has also been suggested that the 
mechanisms responsible for tumor cell death are distinct from those that result in cardiac cell death, 
and/or that cardiomyopathy results when drug-induced damage is combined with particularly 
harmful lifestyle choices (Menna, Salvatorelli, & Minotti, 2008). Current evidence supports 
oxidative stress due to mitochondrial dysfunction, ion dysregulation, energy depletion, and 
disrupted cardiac signaling pathways all contribute to anthracycline-induced cardiomyopathy. As 
evidenced through some of these speculated pathways, anthracycline toxicity may actually amplify 
in the body as the drug is metabolized (Mordente, Meucci, Silvestrini, Martorana, & Giardina, 
2012).  
Oxidative stress is a common and powerful rationale for explaining anthracycline-induced 
cardiotoxicity but is not absolute. Reduction of anthracycline molecules due to enzymatic and non-
enzymatic activity can produce levels of hydrogen peroxide (H2O2) above that of normal levels 
and can result in substantial physical damage to mitochondria (G Minotti, Cairo, & Monti, 1999; 
Giorgio Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004). Under healthy conditions, 
detoxifying enzymes can usually manage clearance of potentially harmful radicals, however, 
cardiomyoctyes naturally have a decreased capacity to resist oxidative damage compared to other 
tissues and are particularly compromised with anthracycline therapy (Doroshow, Locker, & 
Myers, 1980). Mitochondria-based damage from anthracyclines such as membrane disruption, 
organelle swelling and rupture, and injury to the electron transport chain result in the inability to 
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properly metabolize fuel substrates for energy which can lead to mitochondrial death. In terms of 
tumor fighting capacity, this effect has clear benefit. However, the same impact cannot be said for 
cardiomyocytes. Furthermore, it has been demonstrated that anthracyclines directly damage 
mitochondrial DNA (mtDNA) of cardiac muscle, but less so skeletal muscle, likely due to 
intercalation into strands or via production of reactive oxygen species (Adachi et al., 1993; Ashley 
& Poulton, 2009; Dirk Lebrecht, Kokkori, Ketelsen, Setzer, & Walker, 2005). Unfortunately, 
mtDNA damage, electron transport chain dysfunction, and reactive oxygen species production can 
compound and accumulate over time. This latency effect is speculated as the primary reason for 
development of late-onset cardiomyopathy and irreversible damage (D Lebrecht et al., 2007). 
Vascular Toxicity of Chemotherapy 
 
Few studies exist regarding vascular health in BCS, but even low to moderate doses of 
anthracyclines have resulted in preclinical vascular abnormalities and evidence of poor arterial 
health, such as increased arterial stiffness, which may predict future cardiovascular events 
(Chaosuwannakit et al., 2010; Drafts et al., 2013; Grover et al., 2015; Kilicaslan, Piskin, Susam, 
Dursun, & Ozdogan, 2014; Koelwyn et al., 2016). Postmenopausal BCS who received 
chemotherapy have demonstrated greater arterial stiffness than pre and peri-menopausal 
counterparts (Yersal, Eryilmaz, Akdam, Meydan, & Barutca, 2018). Rapid deterioration of 
vascular health within the first month of anthracycline chemotherapy implies acute damage, but 
impairments have been documented up to one year following chemotherapy treatment (Drafts et 
al., 2013; Grover et al., 2015). While markers of aortic stiffness appear to normalize or recover 
years after therapy, more research is needed to evaluate factors that may enhance this recovery or 
prevent initial decline. One of only two published studies evaluating cardiac and vascular health 
in long-term cancer survivors concluded no difference between study groups, yet both participant 
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groups reported substantial exercise participation; approximately 55 minutes per day (Koelwyn et 
al., 2016). With exercise as a known promoter of cardiovascular health in healthy and clinical 
populations, it is possible that participation in exercise was beneficial in improving long-term 
arterial health following chemotherapy (D J Green, Spence, Halliwill, Cable, & Thijssen, 2011; D 
J Green, Spence, Rowley, Thijssen, & Naylor, 2012; Daniel J Green & Smith, 2018). However, to 
our knowledge, no published study exists that evaluates the impact of chronic exercise training on 
vascular health parameters in BCS. The latter mentioned study that found no difference in arterial 
stiffness evaluated cancer survivors but included mostly male subjects who were diagnosed at a 
young age and therefore may have had enhanced ability to withstand damage and/or recover more 
completely (Kearney et al., 2017). Furthermore, the two previously mentioned studies also found 
evidence of stress/exercise-induced cardiac-specific dysfunction in survivors despite relatively 
normal resting measures (Beaudry et al., 2019; Koelwyn et al., 2016). Because the cardiac tissue 
is perfused/served via central arterial supply, it is possible that preceding/upstream central vascular 
dysfunction subsequently damaged cardiac tissue, and vascular damage may only be clinically 
evident when the heart is placed under exertional stress. This elucidates the importance of detecting 
and monitoring vascular health because it may be the first clinical sign of impending 
cardiovascular decline (Erbel et al., 2014; Mozos, Borzak, Caraba, & Mihaescu, 2017). Increased 
surveillance and accelerated detection of vascular dysfunction in concert with effective 
intervention strategies, potentially exercise, would likely provide critical advances in caring for 
BCS. Fortunately, robust and non-invasive markers of vascular health, such as arterial stiffness, 
are feasible to capture and may be successfully implemented in a clinical cancer care setting, but 
have yet to be extensively studied in the literature (Laurent et al., 2001, 2003; Sutton-Tyrrell et al., 
2005; Willum-Hansen et al., 2006).  
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Targeted Therapy 
Unlike the blanket-style approach of systemic chemotherapy, targeted therapies are 
specific to blocking the growth of a cancer cell via a precise receptor or vulnerable characteristic 
of that tumor. Trastuzumab (HerceptinÒ) and pertuzumab (PerjetaÒ)  are two targeted therapies 
used for treatment of primary and metastatic HER2+ breast cancer tumors, respectively. Both are 
humanized monoclonal antibodies that act on specific and different sites of the human epidermal 
growth receptor located on the tumor cell membrane. These drugs prevent dimerization of HER2 
receptors, successfully interfering with cell signaling pathways critical to growth and proliferation, 
which can consequently prevent tumor cell survival (Albini et al., 2011). Trastuzumab has been 
shown to improve disease free survival by 51% and overall survival by 37% when administered 
following anthracycline therapy, providing substantial benefit for HER2+ breast cancer patients 
(Romond et al., 2005; D. J. Slamon et al., 2001; Zeglinski, Ludke, Jassal, & Singal, 2011).  
Cardiotoxicity of Trastuzumab Targeted Therapy 
 
While generally less severe than anthracycline-induced damage and potentially less 
permanent, anti-HER2+ therapies can also induce unwanted cardiac complications like congestive 
heart failure and/or left ventricular dysfunction (Albini et al., 2011; Tan-Chiu et al., 2005; 
Zeglinski et al., 2011). Trastuzumab following anthracycline therapy is the most effective 
combination for HER2+ tumors, improving disease free survival (DFS) by 51% in contrast to non-
anthracycline regimens that only confer 39% DFS, yet comes with the risk of increased likelihood 
of suffering from cardiac damage (Albini et al., 2011; Piccart-Gebhart et al., 2005; Romond et al., 
2005; Zeglinski et al., 2011). Concurrent administration of these agents is particularly threatening 
to the CV system, especially in older patients, increasing incidence of cardiac dysfunction by 27% 
(Seidman et al., 2002) Therefore, standard of care is to administer these drugs sequentially (Albini 
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et al., 2011; Zeglinski et al., 2011). While the precision of directed therapies like trastuzumab has 
contributed substantially to the arsenal of tools available for HER2+ cancer therapy, 
mechanistically the drug targets a ubiquitous receptor, rendering non-tumor cells susceptible to 
injury (Sandoo, Kitas, & Carmichael, 2015; Zeglinski et al., 2011). Cardiac tissue expresses human 
epidermal growth factor receptors, although the degree of expression is debated, resulting in 
vulnerability to the effects of trastuzumab (Albini et al., 2011). The resulting cardiotoxicity usually 
presents more quickly than anthracycline-induced damage but manifests similarly as a decline in 
LVEF. Also dissimilar to anthracycline cardiotoxicity, trastuzumab-induced cardiac decline has 
been attributed to disruption in Neuregulin1 and ErbB receptor signaling pathways, mitochondrial 
function, and cellular energetics rather than structural damage of cardiomyocytes (Brero et al., 
2010; Lee et al., 1995; Rochais & Fischmeister, 2010; Spallarossa et al., 2010). Permanent damage 
to the cardiac tissue from trastuzumab is less common than anthracycline-induced damage and 
recovery of cardiac function is possible following cessation of trastuzumab therapy. Interestingly, 
some patients are also able to restart anti-HER2 therapy without subsequent cardiac symptoms. 
However, the therapy is a modern intervention, thus, long term side effects like cardiotoxicity 
profile are not yet well-known (L. W. Jones, Haykowsky, Swartz, et al., 2007). 
Vascular Toxicity of Trastuzumab Targeted Therapy 
 
 Extremely limited research is available evaluating the impact of trastuzumab on vascular 
specific outcomes in breast cancer survivors (Grover et al., 2015). Two published studies 
evaluating arterial function of BCS found that women treated with trastuzumab targeted therapy 
demonstrate significantly increased arterial stiffness when compared to age and CV risk factor 
matched controls, but less so than what has been shown with anthracyclines alone (Grover et al., 
2015; Yersal et al., 2018). However, most patients in the previously mentioned studies were also 
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treated with anthracyclines so delineating the specific impact of trastuzumab alone is 
complicated. Regardless, pulse wave velocities increased by over 2 m/s in only 4 months 
following therapy which doubles the clinically meaningful change usually seen in approximately 
10 years of aging (C.-Y. Liu et al., 2012; Yersal et al., 2018). More work is needed to determine 
the specific impact of targeted therapies on vascular health. 
Radiation 
Radiation treatment for breast cancer occurs in the adjuvant setting following surgery 
and/or chemotherapy. Radiation uses high energy rays to kill cancer cells which prevents the 
formation of new cancer cells, halves the risk of death from breast cancer recurrence, and 
substantially lowers the risk of breast cancer related death ((M. Clarke et al., 2005; Early Breast 
Cancer Trialists’ Collaborative, Darby, et al., 2011; Veronesi et al., 1993). Radiation, in 
combination with lumpectomy, has been an important and effective advancement for the 
conservative treatment of breast cancer offering patients minimal surgery yet equivalent survival 
benefit as mastectomies (Lichter et al., 1992; Shapiro et al., 1998). For more involved breast 
cancers such as node positive tumors, radiation also has demonstrated benefit for tumor control 
and overall survival in both pre and postmenopausal (Overgaard et al., 1997, 1999). Usually the 
whole breast is irradiated, especially if lymph nodes were found to be positive, but localized 
radiation techniques are being evaluated in clinical trials. Significant improvements in radiation 
administration techniques have allowed increased precision of treatment and decreased adverse 





Cardiotoxicity of Radiation 
Due to the location of vital organs in proximity to breast tissue that may be targeted,  incidental 
exposure of the heart, lungs, and thoracic vessels to radiation can result in substantial organ and 
structure damage (M. Clarke et al., 2005; Cuzick et al., 1994; Marks et al., 2005). A staggering 
62% increase in cardiac deaths has been observed in women who received radiation therapy for 
their breast cancer (Yusuf, Sami, & Daher, 2011). Research supports that radiation can damage 
proper physical contraction of the muscular ventricular wall, leading to perfusion deficits in the 
heart; especially as more heart volume is included in the radiation field in addition to damage of 
the cardiac vasculature (Gyenes, Fornander, Carlens, Glas, & Rutqvist, 1996; Marks et al., 2005). 
Valvular heart disease is recognized especially in women who receive radiation doses in excess of 
30 Gray (Hull, Morris, Pepine, & Mendenhall, 2003). However, radiation-induced damage can 
result independent of detectable changes in left ventricular ejection fraction (LVEF), which is the 
most widely used cardiac surveillance technique for many cancer patients. The silent development 
of heart disease in this population further reiterates the need for consecutive cardiac surveillance 
techniques.  
Vascular Toxicity of Radiation 
 
In addition to cardiac wall damage, radiation has been shown to impair the essential elastic 
properties of the aorta and contribute to increased local arterial stiffening (Kilicaslan et al., 2014; 
Vallerio et al., 2016). Coronary artery disease and risk of vascular-related death is substantially 
increased in women treated with radiotherapy (“Favourable and unfavourable effects on long-term 
survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast 
Cancer Trialists’ Collaborative Group,” 2000).The higher the mean dose of radiation, the greater 
the rate of major coronary events, with an approximate 7.4% increase in risk per Gray received, 
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albeit likely related to older techniques not commonly used today (Darby et al., 2013). 
Improvements in administration techniques, like respiratory gating/breath holding, since the 
1970’s have resulted in decreased risk of cardiovascular disease in patients treated with radiation 
(Hooning et al., 2007). While currently speculative without long term prospective data, 
radiotherapy-induced cardiac perfusion deficits, wall motion abnormalities, and local arterial 
stiffening may collectively or individually contribute to long term cardiovascular disease 
development in cancer patients. 
Hormonal Therapy 
 
Hormonal therapy is a third example of commonly used systemic therapies for women 
with HR+ tumors. Tamoxifen (NolvadexÒ) is a selective estrogen receptor modulator (SERM) 
given to block estrogen from reaching estrogen receptors in ER+ and/or PR+ breast cancer cells. 
Five years of Tamoxifen therapy provides a significant reduction in risk of same-side recurrence, 
ipsilateral recurrence, and death from breast cancer for ER+ tumors (Early Breast Cancer 
Trialists’ Collaborative, Davies, et al., 2011). Both pre and postmenopausal women can take 
Tamoxifen while other hormonal therapies called aromatase inhibitors (AIs; letrozole 
(FemaraÒ), exemestane (AromasinÒ), and anastrazole (ArimidexÒ) are generally used for 
premenopausal women with ER/PR+ breast cancers (Dowsett et al., 2010). Aromatase inhibitors 
interfere with the enzyme necessary for producing estrogen in the body, therefore decreasing 
availability of the hormone ligand and counteracting the growth of HR+ tumor cells. Tamoxifen 
and AIs are commonly administered in an alternating pattern for approximately 5-10 years in the 
adjuvant setting (C. Davies et al., 2013; Z. Yu et al., 2017). While AI therapy use and efficacy 
for breast cancer recurrence is surpassing that of Tamoxifen, decreased serum estrogen, 
hyperlipidemia, and hypercholesterolemia due to AIs’ MOA may be enhancing cardiovascular 
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specific events and remains a concern (Foglietta et al., 2017; L. W. Jones, Haykowsky, Swartz, 
et al., 2007). Tamoxifen, on the other hand, appears to elicit cardioprotective effects related to 
blood lipid profiles due to its actions as an estrogen agonist. Overall, it has not yet been 
determined whether the cardiovascular disease risk profile differences between the two hormonal 
therapies are a result of protective effects of Tamoxifen or harmful effects of AI’s, but these 
changes may predispose the survivor to unwanted comorbidities (Foglietta et al., 2017; 
Thurlimann et al., 2005). 
Cardiotoxicity of Aromatase Inhibitors 
 
Estrogen is thought to play a protective role in terms of cardiovascular health based on 
the relatively low incidence of cardiovascular disease in premenopausal compared to 
postmenopausal women, and between women and men (Kalin & Zumoff, 1990; Leening et al., 
2014). Aromatase inhibitors are primarily prescribed for postmenopausal BCS, many of who 
present at baseline with existing cardiovascular risk factors and who may further increase risk 
through behavioral changes like physical inactivity and poor diet during cancer therapy (Irwin et 
al., 2003; Rock et al., 1999; Wagoner, Choi, et al., 2019; P. W. F. Wilson, D’Agostino, Sullivan, 
Parise, & Kannel, 2002). Therefore, additional reduction in circulating estrogen due to effects of 
aromatase therapy can further exacerbate the potential of developing cardiovascular disease in 
BCS, especially those who are postmenopausal (Amir, Seruga, Niraula, Carlsson, & Ocana, 
2011). Evaluation of large endocrine therapy trials for cardiac safety reveals heterogeneous 
results related to cardiovascular risk, events and cardiac-specific mortality (Foglietta et al., 
2017). 
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Vascular Toxicity of Aromatase Inhibitors  
Aromatase inhibitors are thought to elicit negative effects on the vascular endothelium 
disrupting vasodilation, coagulation and antioxidant regulation, potentially predisposing 
survivors to atherosclerosis and/or hypercholesterolemia (Mendelsohn, 2002; Nathan et al., 
2001). Women receiving aromatase therapy have demonstrated increased arterial stiffness and 
less favorable lipid profiles but a distinguished, vascular-specific toxicity due to AI damage 
versus Tamoxifen protection has not yet been observed (Foglietta et al., 2017; Yersal et al., 
2018).  
Summary 
Primary breast cancer therapies have the potential to significantly disrupt cardiovascular 
health, with the impact of some treatments more toxic, evident, and/or well-studied than others. 
Further work is needed to clarify each therapy’s damage-inducing mechanism and the organs and 
tissues that may be most vulnerable. Further, the ability to feasibly and accurately monitor and 
detect early deterioration in the cardiac and vascular system would likely provide opportunity for 
earlier intervention and potentially curb the incidence of permanent cardiovascular disease. 
Additionally, the potential role of complementary therapies such as exercise to protect or 
promote cardiac and vascular-specific health of BCS in the adjuvant setting warrants 
investigation.  
Section III: Cardiorespiratory Fitness: Oxygen Cascade and Hemodynamics 
 
The Oxygen Cascade 
 
The cardiovascular system is responsible for oxygen transport and utilization in the body. 
Cancer therapy-induced damage can directly threaten the vigor of the integrated cardiac, vascular 
and peripheral oxygen-associated structures essential for life. Cardiorespiratory fitness can be 
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measured directly through maximal exercise testing and is quantified in terms of maximal aerobic 
capacity or VO2max. This maximal oxygen consumption is also described mathematically in the 
Fick equation (VO2max = CO * a-vO2diff) as a product of cardiac output (stroke volume * heart rate) 
times the arterial venous oxygen difference (a-vO2diff). An individual’s aerobic capacity is 
therefore a product of central and peripheral components; the former dominated by the heart and 
conduit vasculature, and the latter by microvasculature, skeletal muscle, and mitochondria 
(Hoppeler & Weibel, 1998). In series, these components reflect links in the oxygen cascade – a 
model describing the flow of oxygen delivery, transport, and consumption. Mathematically, it can 
be demonstrated that impairments, individual or in combination, in this cascade will result in an 
overall impaired aerobic capacity (VO2max). Interestingly, decreased aerobic capacity is a well-
established phenomenon observed in breast cancer patients and is critical due to the established 
relationship between depressed maximal aerobic capacities with increased morbidity and mortality 
(L. W. Jones et al., 2010; Terence Kavanagh et al., 2003). From diagnosis to years beyond, breast 
cancer patients have demonstrated aerobic capacities up to 30% lower than age-matched, non-
cancer controls (L. W. Jones, Courneya, et al., 2012). This loss of aerobic capacity has been 
observed despite preserved stroke volume, and survivors demonstrate impairments in contractility 
and an inability to meet functional demand (Koelwyn et al., 2016). Therefore, determinants of 
oxygen transport other than central cardiac factors must be compromised, but have not yet been 
well studied in this population.  
Peripheral components of the oxygen cascade, like microvascular function, are less well-
researched than central components, especially in breast cancer populations, and warrant further 
evaluation. Furthermore, the vulnerability of the different links in this chain of oxygen utilization, 
and their associated degree of contribution to overall aerobic capacity are not clearly understood 
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(Jessica M Scott et al., 2018). Only a handful of studies have concurrently evaluated overall aerobic 
capacity with potential determinants in BCS, and have observed central performance impairments 
with implication of peripheral deficiencies, especially at higher workloads (Beaudry et al., 2019; 
L. W. Jones, Haykowsky, Pituskin, et al., 2007b; Koelwyn et al., 2016). Improving understanding 
of vulnerable cardiovascular components in potential need of surveillance, will allow researchers 
the opportunity to propose and design interventions specific to protecting or repairing vulnerable 
links as a way to preserve systemic oxygen consumption. 
From a prevention and treatment perspective, it is important to recognize many newly 
diagnosed breast cancer patients present at baseline with exercise intolerance and substantial 
cardiovascular disease risk factors such as physical inactivity and obesity due to lifestyle 
characteristics and habits (Beaudry et al., 2019; Calle, Rodriguez, Walker-Thurmond, & Thun, 
2003; C. A. Clarke, Purdie, & Glaser, 2006; L. W. Jones, Haykowsky, Swartz, et al., 2007). While 
these initial risk factors approximate that of the general population, further decreases in physical 
activity from diagnosis to survivorship in BCS can enhance weight gain, even with stable caloric 
intake, exacerbating an already unhealthy cardiovascular profile and impaired aerobic capacity 
(Beaudry et al., 2019; Irwin et al., 2003; Rock et al., 1999). Increasing evidence supports that long-
term sedentary lifestyles in women with breast cancer accelerates cardiovascular aging resulting 
in compromised performance as a whole, even before cancer therapy administration (Beaudry et 
al., 2019). Compounded with cardiotoxic cancer therapies, this milieu of insults (termed “multiple 
hit”) has the potential to severely disturb both short and long term cardiovascular outcomes in 
BCS, especially if no interventions are implemented to encourage lifestyle changes (L. W. Jones, 
Haykowsky, Swartz, et al., 2007; Jessica M Scott et al., 2018). 
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Cardiovascular Hemodynamics: Central Aspects 
The first two components of the Fick equation (stroke volume and heart rate) depend on 
central cardiac and arterial health. Arteries in the body are structured to allow stretching and 
contracting based on blood volume shifts with large arteries acting as both a conduit and 
cushioning system, best represented by the actions of the aorta during heart contractions. Vascular 
compliance of large arteries is desirable for healthy vascular function but naturally decreases down 
the arterial tree as peripheral arteries are more muscular and less elastic than their proximal 
counterparts (Nichols & McDonald, 1972). As the heart pumps and ejects blood into the 
vasculature (stroke volume), pressure waves propagate through the circulatory system. This 
coupling of cardiac and vascular compliance is directly related to exercise capacity (Hundley et 
al., 2001; Kass, 2005). Pressure waves are amplified or dampened through a series of highly 
complex interactions based on the distensibility, architecture of vessel walls, and changes or 
bifurcations of the vessel channels as they extend into the periphery (Laurent et al., 2006). As 
arterial stiffness increases in vessels via aging, disease, or structure, forward-traveling pressure 
waves exuded by the heart can be propagated or reflected off harder vessel walls with increasing 
speed (Boutouyrie et al., 1992). This speed of travel can be quantified by carotid-femoral PWV, 
the gold standard measure of arterial stiffness, and an independent predictor of cardiovascular 
events and mortality (Laurent et al., 2001, 2003). The stiffer an artery, the faster a wave propagates 
through the circulation and is reflected back on organs like the heart, potentially damaging the 
organ and/or compromising pumping action (Coutinho, Turner, & Kullo, 2011; Laurent et al., 
2006). Amplification of the central pulse pressure (at the heart) due to increased velocity of 
reflected pressure waves and poorer microvascular health can be described as the augmentation 
index (AIx).  PWV and AIx are related but differ in that PWV describes regional arterial stiffness 
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(i.e. in the area of assessment: radial, brachial, carotid-femoral), and AIx changes based on 
systemic arterial stiffness influenced by heart rate, whole-body reflected wave amplitudes, and 
PWV (Kim & Braam, 2013). Nonetheless, greater arterial stiffness (i.e. indicated by faster PWV 
and higher AIx) indicates less elastic, more collagenous vasculature and a less favorable 
cardiovascular profile (Sutton-Tyrrell et al., 2005; Weber et al., 2004). Clinical conditions such as 
diabetes and peripheral artery disease can result in compromised vascular health as exhibited by 
increased PWV (Benetos, Laurent, Hoeks, Boutouyrie, & Safar, 1993; Boutouyrie et al., 1992; 
O’Rourke, Staessen, Vlachopoulos, Duprez, & Plante, 2002). While significantly less studied 
compared to diabetes and peripheral artery disease, cancer survivors also exhibit increased arterial 
stiffness as measured by PWV, likely due to varying vascular-related toxicities from cancer 
therapies (Mozos et al., 2017; Souza et al., 2018). This unfavorable vascular profile may be a 
contributor to the increased incidence of cardiovascular mortality observed in BCS. 
From a cardiac-specific perspective, depending on timing, pressure waves reflected back 
on the heart can amplify central pressure placing a higher workload demand on the cardiac system.  
Similar to consequences of long-term afterload pressure seen in other clinical pathologies, this 
effect can damage vessels and associated tissues, and can compromise the volume of blood ejected 
(stroke volume) into the body (Laurent et al., 2006). Pressure waves that collide with the heart 
during systole (faster PWV) augments afterload pressure at the left ventricle, increasing pulse 
pressure (increased AIx), decreasing stroke volume, and inducing higher mechanical stress on the 
heart. Conversely, collision during diastole (slower PWV) is beneficial and enhances perfusion of 
the cardiac tissue via coronary arteries (decreased AIx). Balancing the heart’s physical pumping 
demand with the requisite to supply its own tissue with oxygen is critical to cardiac performance, 
as the heart itself only perfuses during diastole (Hoffman & Buckberg, 2014). If stroke volume is 
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compromised (for example due to anthracycline-induced cardiotoxicity), the heart must increase 
contraction rate (heart rate) to maintain cardiac output. This is a natural response of the cardiac 
system observed under stress or during exercise but may become less transient if the 
heart/vasculature becomes chronically pathologic. Over time, if stroke volume cannot be 
maintained and heart rate increases to conciliate, perfusion of the heart may be compromised which 
increases risk of cardiac ischemia (Hoffman & Buckberg, 2014).  An index using diastolic 
pressure, systolic pressure, and time integrals over a cardiac cycle has been developed using 
characteristics derived from a validated central pressure waveform (Hwang et al., 2014). This 
value is termed the Buckberg Index and reflects cardiac subendocardial viability; a parameter of 
diastolic function. While index values are not specifically intended to diagnose ischemia, serial 
measures may capture changes that illustrate functional deterioration and help identify those at 
risk of diminishing cardiac performance (Budinskaya et al., 2017; Hoffman & Buckberg, 2014). 
This measure, derived from the waveform of validated and automated tonometry systems used for 
pulse wave analysis, has been minimally studied and never reported in the breast cancer literature, 
to the best of our knowledge (Butlin et al., 2013). The Buckberg index, in addition to PWV and 
AIx, could be an important, non-invasive, hemodynamic measure to obtain serially when 
monitoring patients like BCS who have particular cardiovascular concerns. 
Non-Invasive Measurement of Central Cardiovascular Health 
Pulse wave velocity, AIx, and Buckberg Index can be quickly and reliably captured with 
clinically feasible, automated, non-invasive technologies such as the FDA-approved, AtCor 
SphygmaCor XCEL devivce (Hwang et al., 2014; Williams et al., 2006). This device quantifies 
pressure waves at the periphery, and based on a validated transfer function, describes the central 
pressure characteristics at the heart (producing AIx and Buckberg Index values) (Butlin et al., 
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2013). Central aortic pressures and characteristics are superior to peripheral pressures in describing 
cardiac stress, however, these technologies are not generally utilized in standard oncology clinics 
(Wassertheurer et al., 2010). Failing to evaluate central pressures, AIx, and Buckberg indices may 
compromise more detailed understanding of patient cardiovascular health status. In terms of BCS 
who are at higher risk of cardiovascular and coronary artery disease due to potentially cardiotoxic 
therapies, serial cardiovascular surveillance with the previously described non-invasive 
technologies may offer unique supplemental diagnostic and prognostic value for identifying 
important, centrally-located cardiovascular vulnerabilities  (Harris et al., 2006; L M Jones et al., 
2013). However, it should be recognized that values such as the Buckberg Index obtained from 
pulse wave analysis are derivatives, not direct measurements, and should therefore be interpreted 
with caution until further direct validations exist. 
Cardiovascular Hemodynamics: Peripheral Aspects 
The latter portion of the Fick equation (a-vO2diff) is predominately driven by skeletal 
muscle, especially during exercise, and reflects microvascular and mitochondrial function as 
peripheral components related to oxygen utilization (Hoppeler & Weibel, 1998). These 
components of the oxygen cascade have not received extensive evaluation in BCS, but limited 
evidence suggests function is compromised (Didier et al., 2017; Ederer et al., 2016). While 
mechanisms of action between cardiotoxic damage and tumor cell damage from chemotherapy 
may differ, mitochondria have emerged as mutual primary cellular targets of anthracycline 
therapy. These organelles are responsible for extracting oxygen from microvasculature, managing 
oxidative stress, balancing calcium concentrations, and producing sufficient energy through 
aerobic metabolism. Certain chemotherapies used in treatment of breast cancer elicit their tumor-
killing effects by disrupting or destroying proper mitochondrial function (Henriksen, 2018; 
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Mordente et al., 2012). However, the somewhat ambiguous nature of chemotherapy negatively 
impacts functional tissue like skeletal muscle which is essential for producing movements required 
for activities of daily living and exercise(Ashley & Poulton, 2009; Poole, Copp, Ferguson, & 
Musch, 2013).  Marked loss of volume of functional, force-producing tissue, and/or impairments 
in ability to extract or utilize oxygen in the mitochondria limits functional capacity and is a 
significant concern for BCS (A A Kirkham, Bland, Sayyari, Campbell, & Davis, 2016; Kutynec, 
McCargar, Barr, & Hislop, 1999; Mordente et al., 2012). These consequences of chemotherapy 
could be mathematically quantified and vindicated as contributors to decreased systemic aerobic 
capacity by minimizing the a-vO2diff variable in the Fick equation. While limited data exists, 
research using infrared spectroscopy suggests impairments in cancer survivors’ abilities to 
properly deliver and extract oxygen during exercise and is speculated to be a result of 
mitochondrial dysfunction (Didier et al., 2017; Ederer et al., 2016). Fortunately, non-invasive 
techniques using near infrared light spectroscopy (NIRS) have provided researchers and clinicians 
means to evaluate surrogate markers of mitochondrial function by monitoring deoxyhemoglobin 
(HHb) signals in microvasculature of muscles during exercise. Based on light absorption and 
refraction properties, different wavelengths of light are absorbed by deoxy and oxyhemoglobin 
allowing researchers to distinguish the two proteins in vessels approximately 1-2mm in diameter 
(Mancini et al., 1994). As a muscle completes more aerobic work, the consumption of oxygen and 
production of deoxyhemoglobin should increase, reflective of properly functioning 
microvasculature and skeletal muscle mitochondria. The rate of consumption over time, especially 
when evaluated in series in the same individual, may help identify potential impairments in 
microvascular circulation and mitochondrial function. NIRS only provides a local “snapshot” of 
microvascular status, and has some limitation and assumptions for proper use, but is a highly 
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feasible and validated measure when used appropriately (Lucero et al., 2018; Mancini et al., 1994). 
NIRS has been extensively used in clinical populations such as peripheral artery disease and 
diabetes mellitus, but has been minimally implemented in cancer patients, and never in a group of 
all breast cancer survivors to the best of our knowledge (Barroco, Sperandio, Reis, Almeida, & 
Neder, 2017; Lanfranconi et al., 2014; Layec et al., 2016). 
Section IV: Exercise for Cardiorespiratory Health and Fitness 
Well designed and implemented exercise can have an important role for improving 
cardiorespiratory health, fitness, fatigue, and quality of life among other factors in the breast cancer 
population (Battaglini et al., 2014b; A A Kirkham et al., 2016; McNeely et al., 2006; Schmitz et 
al., 2010). Recent publications support exercise as an effective adjuvant therapy for increasing 
cardiorespiratory fitness in BCS and other clinically relevant outcomes (A A Kirkham et al., 2016; 
J M Scott et al., 2018). Interestingly, while exercise can positively impact multiple organ systems, 
enhance overall cardiovascular reserve capacity, and is an established therapy to improve 
exertional intolerance for patients with heart failure (Pandey et al., 2015), the same utility has been 
less consistently appreciated in the breast cancer population (L. W. Jones, Haykowsky, Swartz, et 
al., 2007; Lakoski et al., 2012; Mora, Cook, Buring, Ridker, & Lee, 2007). However, it has been 
shown that increasing levels of exercise is associated with a decrease in incidence of cardiovascular 
events in women with non-metastatic breast cancer (L. W. Jones et al., 2016). All-cause and 
cancer-specific mortality have been reduced by 13% and 15%, respectively, in non-cancer 
populations following an increase in cardiorespiratory fitness of approximately 3.5mL/kg/min (1 
MET) (Barlow et al., 2012; Kodama et al., 2009; Myers et al., 2002).  
A significant gap in the field of exercise oncology is the lack of clarity between structured 
exercise interventions and specific biologic/physiologic cardiovascular changes they elicit, 
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especially as they relate to overall cardiorespiratory fitness. Cardiovascular outcomes other than 
cardiorespiratory fitness are rarely reported but warrant attention as they may be important and 
unique indicators of heart, macro, and microvascular health and may be more feasibly obtained 
and monitored in clinic settings than a CPET (Jessica M Scott et al., 2018). Determinants of aerobic 
capacity (i.e. those representative of the components in the Fick equation) have also been 
minimally studied in concurrence with systemic aerobic capacity measurements (Beaudry et al., 
2019; L. W. Jones, Haykowsky, Pituskin, et al., 2007a) Systemic cardiorespiratory fitness can be 
improved with properly designed and implemented exercise, which suggests cardiac and vascular 
determinants supporting the overall oxygen consumption are improving either independently or as 
a system. This phenomena is well-described in non-cancer populations (M. G. Wilson, Ellison, & 
Cable, 2016) and supporting and speculated mechanisms will be explained below. However, the 
impact of exercise training on individual components, especially those related to vascular health 
and peripheral oxygen metabolism, have not been well studied or reported in BCS (Beaudry et al., 
2019; J M Scott et al., 2018). Evaluating these more intricate relationships may provide an 
enhanced understanding of specific vulnerable components of a BCS’s cardiovascular system 
following cancer therapy, and the unique contribution of components to systemic oxygen 
consumption. Long term, these components may develop as new targets for consecutive 
surveillance or intervention throughout a BCS’s journey.  
Mechanisms of Exercise-induced Changes 
 Exercise has long been appreciated as a strategy to broadly improve cardiovascular health. 
Mechanisms of exercise-induced improvements revolve around structural and functional changes 
in the myocardium and endothelium (M. G. Wilson et al., 2016). The degree of benefits/changes 
are generally dependent on the type, intensity, duration, and frequency of exercise activity but in 
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general, greater amounts of exercise appear to maximize cardiovascular health (T Kavanagh, 1983; 
M. G. Wilson et al., 2016). Athletes commonly exhibit superior fitness, enlarged heart structures, 
and lower resting blood pressures when compared to sedentary controls as a result of continuous 
engagement in structured physical activity(M. G. Wilson et al., 2016). These changes promote 
cardiovascular efficiency and enhance exercise capacity due to improvements in ability to uptake, 
distribute, and utilize oxygen within the body. Therefore, exercise training can be used, alone or 
in concert with pharmacologic interventions, to target vulnerable systems and improve outcomes 
for at-risk populations. 
Cardiac Benefits of Exercise Training 
The majority of cardiac hypertrophy in the heart following exercise training relates to the 
effect of hemodynamic loads during exertion inducing enlargement of cardiomyocytes. Endurance 
exercise training (running, cycling, swimming etc. for long periods of time) elicits blood volume 
stress on the heart due to an increase in venous return and end diastolic volume of the left ventricle. 
This stimulus causes immediate improvements in ejection fraction/stroke volume due to the Frank-
Starling stretch-contract reflex (Shiels & White, 2008). Chronic endurance training causes the 
heart to elongate by adding sarcomeres in series, and to increase long-axis torsion or “wringing” 
which improves overall cardiac output and concurrent contractility (Mihl, Dassen, & Kuipers, 
2008; Nakatani, 2011). Improvements in cardiac output directly enhance systemic aerobic capacity 
as described previously in the Fick Equation. Resistance or strength training elicit pressure stress, 
specifically increased afterload, on the heart due to occlusion of downstream vessels by contracting 
muscles. In order to counteract afterload pressure and ensure ejection of blood from the heart, 
contraction force at the heart must increase. Cardiac tissue responds to chronic afterload pressure 
stimuli by adding sarcomeres in parallel, eventually thickening the walls of the ventricles and 
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increasing force-producing potential (Mihl et al., 2008). However, increases in cardiac contractile 
strength due to strength training has shown minimal impact on overall aerobic capacity in BCS, 
unlike the adaptations of endurance training, but provide other beneficial systemic effects pertinent 
to BCS (A A Kirkham et al., 2016; Sasso et al., 2015; Schmitz et al., 2010). 
Vascular Benefits of Exercise Training 
In healthy populations, repeated or chronic exercise can induce substantial improvements 
in vascular function and structure that in turn contribute to reduced cardiovascular risk (Daniel J 
Green & Smith, 2018). The same effects have not been thoroughly studied in cancer populations, 
although similar adaptations may occur, but may provide particular benefit for this vulnerable 
population through similar mechanisms. During acute exercise, K+, H+, and CO2 released from 
active muscle in combination with the effects of sheer stress inside vessel walls, result in release 
of nitric oxide (NO) in blood vessels. Shear stress is essential for vascular adaptation and triggers 
the release of nitric oxide from healthy endothelium. In healthy systems, NO acts as a potent 
vasodilator which enhances muscle blood flow and perfusion, allowing for enhanced oxygen 
delivery (Daniel J Green, Maiorana, O’Driscoll, & Taylor, 2004). Repeated bouts of exercise, 
and therefore repeated exposure to hemodynamic loads and shear stress, result in structural and 
functional changes in vessels that enhance vasodilatory effects, improve wall:lumen ratios, 
increase capillary networks, and reduce systemic arterial resistance, benefitting the vascular 
system as a whole (D J Green et al., 2011; Daniel J Green & Smith, 2018). These changes result 
in an enhanced ability to accommodate blood volume and pressure stress, may reduce unwanted 
central pressures at the heart, and may augment both the delivery of oxygen and removal of 
waste in working muscle (D J Green et al., 2012; Daniel J Green et al., 2004; Sugawara et al., 
2007). These responses are evident in populations with intact autonomic systems but in 
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populations like BCS with demonstrated autonomic dysfunction and potential endothelial 
damage, the effects may be dampened or absent (Lakoski et al., 2015; J M Scott et al., 2014). 
Two recently published studies observed attenuated blood flow response in cancer survivors, 
which negatively impacts proper utilization of oxygen at working tissue, but mechanisms 
responsible for these decrements are not yet understood (Didier et al., 2017; Ederer et al., 2016). 
Furthermore, it is relatively unknown the impact or potential benefit of chronic exercise training 
on blood flow in cancer populations. 
Oxidative Stress Benefits of Exercise Training 
 Exercise naturally produces free-radicals in mitochondria of working cells but chronic 
exercise training reduces oxidative damage, improves antioxidant enzymes, and reduces 
inflammation by upregulating redox-sensitive defense mechanisms (Hoppeler & Weibel, 1998; 
Mordente et al., 2012). Chronic training, especially endurance, upregulates mitochondrial 
biogenesis as a response to the demand for increased oxygen consumption, improved fatty acid 
oxidation, and increased ATP production. Increased mitochondrial density and number in a 
working muscle provide the means for improved volume and efficiency of oxygen extraction 
from the blood and can (in addition to vascular effects) directly increase the latter portion of the 
Fick equation, increasing overall aerobic capacity. Exercise-induced oxidative stress has also 
been speculated as a potential cardioprotectant via the neuregulin protein signaling pathway 
(Peng, Chen, Lim, & Sawyer, 2005). This is the same pathway disrupted in HER2+ breast 
tumors and exercise-effects may be particularly intriguing in this subset of survivors. Unlike 
muscle-specific benefits, vascular-specific benefits from chronic oxidative stress stimuli from 
exercise training are not yet well understood but studies are advancing (Daniel J Green, Hopman, 
Padilla, Laughlin, & Thijssen, 2017). 
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Response Heterogeneity and Power of Predictors 
While most research presents primary study outcomes like DVO2peak in terms of mean 
response, the heterogeneity of response both within and between study outcomes in BCS has 
recently become more appreciated (J M Scott et al., 2018). Some patients may respond more/less 
than others to particular exercise interventions or medical therapies. This has become a particular 
interest in the field of exercise oncology, especially related to patient-centered care, and has 
highlighted the potential utility of baseline predictors. The ability to stratify patients by risk 
profiles into appropriate intervention modalities at baseline using feasibly obtained physiological 
biomarkers would vastly improve the ability to provide the most effective, appropriate and targeted 
treatments to the right patients. While gold standard evaluations like a cardiopulmonary exercise 
testing (CPET) or cardiac MRI’s can be used at baseline to risk stratify patients, costs, logistics, 
and feasibility complicate implementation. In terms of cardiovascular risk predictors in BCS, there 
is no consistent approach or clinical indicator/biomarker used to evaluate long-term outcomes 
(Armenian et al., 2017). Indication of cardiovascular damage may not become evident until 
approximately 5-10 years after treatment completion which necessitates the need for long-term 
surveillance in this population (Bulten et al., 2014). The non-invasive cardiovascular measures 
proposed in this study may help provide clinicians and researchers with feasible, potentially 
prognostic tools to evaluate and monitor patient outcomes consecutively long term and thereby 
improve our ability to detect changes (L M Jones et al., 2013). Blood biomarkers are also receiving 
attention as potential powerful indicators of long-term outcomes. The protein encoded by the 
tumor suppressor gene p16INK4a has recently been evaluated and established as a biomarker of 
aging (Y. Liu et al., 2009; Tsygankov, Liu, Sanoff, Sharpless, & Elston, 2009). Cancer patients 
treated with chemotherapy have demonstrated accelerated molecular aging in peripheral blood T-
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cells (Sanoff et al., 2014). Interestingly, the 10-14 years of molecular aging observed via increased 
p16 INK4a expression in the previously mentioned study approximates the same aging phenomenon 
related to aerobic capacity observed in cancer patients following therapy (L. W. Jones, Courneya, 
et al., 2012). The relationship between p16 INK4a and VO2, and other functional or clinical 
outcomes, has yet to be evaluated but warrants further investigation (Sanoff et al., 2014). 
 In summary, the primary gaps in the literature and field of exercise oncology that this 
study intends to reduce include a paucity of data regarding vascular health profiles of BCS and 
evaluating how exercise participation may change arterial health of BCS. Further goals include 
determining how components of the oxygen cascade, such a vascular health outcomes, influence 





CHAPTER THREE: METHODOLOGY 
Subjects  
Two cohorts of women were recruited for the proposed study. One group was early stage, 
non-metastatic BCS who were within one year of completing primary cancer therapy (surgery, 
chemotherapy, radiation), and were otherwise free from overt cardiovascular, metabolic, 
orthopaedic complications. The second group was an age and physical activity matched group of 
women who did not have a cancer history and were otherwise healthy. Both groups required 
physician clearance to participate and were cleared by a cardiologist before completion of any 
maximal exercise testing. Both groups completed study-related testing (described later) on 2 days 
at baseline, and then completed 16-weeks of progressive, supervised aerobic and strength training 
exercise at the UNC GRH exercise facility, followed by 2 days of post testing mirroring pre-
testing.  
Recruitment 
Clinical Research Associates (CRAs) identified potential study participants through a 
review of daily clinic schedules for patients seen at the North Carolina Cancer Hospital. The CRAs 
secured the approval of the treating oncologist prior to approaching the patient about the study. 
Get REAL & Heel was open to patients seen at other sites, provided they met eligibility criteria 
described previously and had proof of clearance for participation from their oncologists via email 
or letter. Non-cancer controls were be recruited by research team members using flyers, emails, 
and word-of-mouth contact in the local community. All interested persons were screened and 
consented on a consecutive first come first served bases. Potential participants were contacted by 
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research team members to discuss the study and allow survivors time to ask any questions. Those 
interested in participating in the GRH study were asked to sign a UNC IRB-approved informed 
consent form before completing any study related assessments. 
Instrumentation 
A Physical Activity Readiness Questionnaire (PAR-Q) and a medical history 
questionnaire were used to determine whether or not approval by physician would be required to 
take part in the study prior to officially signing consent to participate. The short version of the 
International Physical Activity Questionnaire (IPAQ) was used to confirm current physical 
activity participation in both groups. Literature supports breast cancer survivors report 
substantial levels of physical inactivity throughout the cancer care continuum, so exercise 
participation was not used as an exclusion in our breast cancer survivors (Kwan et al., 2012). To 
best mirror this population, recruited control participants did not complete more than two days of 
structured exercise at baseline.  
A portable stadiometer (Perspective Enterprises, Portage, MI) was used to measure height 
(to the nearest 0.5 cm) and weight (to the nearest 0.1 kg). A Hologic (Discovery W) Dual X-ray 
Absorptiometry (DEXA) was used to assess body composition. An electrocardiography system 
(GE Medical Systems, Milwaukee, Wisconsin) was used to obtain 12-lead ECG tracings for 
cardiologist review. The SphygmaCor XCEL device (AtCor Medical, Sydney, Australia) was used 
to collect PWV, AIx, Buckberg Index, and other descriptive hemodynamic measures at rest. A 
Polar telemetry system (Polar Electro Inc., Lake Success, NY) was used to monitor heart rate 
during maximal exercise testing. A Lode electronically-braked cycle ergometer was used to 
complete an incremental 15 watt/min cardiopulmonary exercise test with complete gas exchange 
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analysis using ParvoMedics metabolic system. The UNC GRH exercise program facility was used 
for the 16-week exercise training intervention.  
Research Design Overview 
In this non-randomized study, all subjects completed two laboratory visits prior to (pre-
test) and immediately following (post-test) a 16-week supervised exercise intervention as 
illustrated in Table 1. Both laboratory visits were conducted in the Exercise Oncology Research 
Laboratory (EORL) in the department of Exercise and Sport Science at UNC-Chapel Hill. Pre and 
post testing were completed within a two-week window. The first day of testing included: fasted 
body composition, 12-lead ECG evaluation, fasted and resting cardiovascular measures, and 
familiarization to the exercise test on the cycle ergometer. The second day of testing included the 
true maximal exercise test on the cycle ergometer with a 3-minute post completion lactate 
measurement. The 16-week exercise intervention included a combination of progressive aerobic 
and strength training for 3 small group sessions per week at approximately 1 hour per session at 
the UNC GRH exercise facility. Post-testing followed the exact same format as pre-testing (minus 
ECG) and occured over a two-week timeframe immediately following conclusion of the 16-weeks 
of exercise training. 
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After subjects demonstrated interest to participate in this study and met baseline inclusion 
criteria (clear medical history, ≤2 days/week exercise, physician approval if needed), subjects 
were informed of pre-assessment guidelines to follow in the day(s) prior to physical fitness pre 
and post-testing and were scheduled for pretesting in the EORL. This included being fasted for 
most of the day one assessments and no caffeine for either testing day, but participants were 
encouraged to stay hydrated with water. On the first day of pre-testing, subjects read and signed 
an informed consent form and were assigned a 4-digit identification code. The primary 
investigator verbally insured the subject adhered to pre-assessment guidelines. The primary 
investigator collected demographic information of each subject including age, race, sex, height 
and weight. Cancer-specific information was collected from electronic medical records for 
survivors who agreed to participate and release related information.  
Following demographic data collection, each subject completed in the following order: 
one DEXA assessment, one ultrasound scan of the vastus lateralis, resting cardiovascular 
measurements (AIx, Buckberg Index, PWV) taken in duplicate and averaged for analysis, one 
resting 12-lead ECG, one blood draw for complete blood count and p16INK4a, one 6-minute walk 
test (6MWT), two timed up-and-go tests with the fastest time recorded for analysis, and a 
familiarization session on the bike including wearing a mask and completing submaximal 
exercise up to 75% of heart rate reserve. Participants were required to be fasted (overnight) for 
the first five assessments on day one but were encouraged to bring and consume a light snack 
before the walking test and bike familiarization.  
Following the first day, research team members obtained cardiologist review and 
approval of the 12-lead ECG tracing, and scheduled the participant for the second day of testing. 
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The second day included a maximal exercise test on the cycle ergometer. Participants were fitted 
with appropriately sized metabolic mask for gas exchange analysis. Participants completed warm 
up then an incremental (15 watt/min) ramp maximal exercise test on the cycle ergometer. 
Following completion of testing days, participants were enrolled in the 16-week exercise 
intervention. Following completion of the intervention, participants were scheduled to return to 
the EORL for post-testing and completed the same assessments in the same order as pre-testing. 
The blood draw was not completed at post testing. 
Assessments 
Height and Body Mass  
Subject’s height was measured without shoes, standing with their back against the 
stadiometer and looking straight ahead. Body mass was measured without shoes and in minimal 
clothing using an electronic scale.  
Body Composition 
Total body weight-mass (BW) and compositional aspects of lean body mass (LBM), fat 
tissue mass (FM), and percentage body fat (% BF) was examined for patient demographics using 
standard DEXA screening procedures.  
Non-invasive cardiovascular measurements 
Gold standard measures of arterial stiffness including PWV and AIx, in addition to other 
hemodynamic variables, were collected using the using the SphygmorCor XCEL device (AtCor 
Medical, Sydney, Australia) following standard manufacturer guidelines and protocols 
(following 10-15 minutes of supine rest). For pulse wave analysis, an inflatable cuff was placed 
around the upper arm. Survivors had the cuff placed on the non-surgical side to avoid any 
complications with lymphedema and control subjects were standardized to the left side. 
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Contralateral placement of the cuff has been shown to yield congruent readings (Hwang et al., 
2014). The cuff as electronically inflated/deflated and central and peripheral blood pressures, 
AIx, and Buckberg Index were measured by the device and software. Measures were taken in 
duplicate and averaged for analysis. For Pulse Wave Velocity, participants lied in a supine 
position with a blood pressure cuff on upper thigh of one side of the body to detect femoral 
pulse, and a handheld tonometer at the ipsilateral carotid artery. Segmental measurements 
between the cuff and the tonometer were made and were necessary for the software to estimate 
the linear distance the pressure wave travels in the conduit vessel of interest. The tonometer was 
placed on the carotid artery and the leg cuff inflated electronically. Once a sufficient pulse wave 
was detected, the carotid-femoral PWV reading was captured over 10 seconds. Measures were 
repeated twice or until there was no more than a 10% difference between measures. PWV was 
automatically calculated as the distance between the detected carotid artery pulse and the 
detected femoral artery pulse divided by pulse transit time. 
Blood Draw 
As part of an exploratory analysis (described in statistical analysis section) evaluating a 
novel biomarker of aging, p16INK4a, a complete blood count (CBC) and p16INK4a was assessed via 
intravenous blood sample for all participants. Blood draws took place after the resting body 
composition and vascular measures on the first day pre-testing. p16INK4a was assessed using 
standard blood draw techniques from a 10mL blood sample in an EDTA tube. A CBC with 
differential was completed and was necessary to normalize biomarker expression to the total 
lymphocyte count. De-identified samples were delivered to the Sharpless laboratory in the 
Lineberger Cancer Center for p16INK4a analysis. Blood samples were labeled with anti-CD3 
microbeads for T cell population prior to purification using AutoMACS pro (Miltenyi biotec). T 
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cells with purity exceeding 90% were used for RNA extraction. TaqMan RT-PCR were performed 
in duplicates and 18S were used as controls to measure the expression of p16INK4a. Additionally, 
TaqMan includes control samples of known p16INK4a and were run as additional methodological 
control.  
6-Minute Walk Test 
The 6-minute walk test is a clinically feasible test used to assess aerobic endurance and 
will be completed following resting cardiovascular measures on the first day of testing. 
Participants were encouraged to walk as quickly as possible around a 50-yd rectangular course 
for a total of 6 minutes. Participants had to complete the testing at a walk; jogging or running 
was not be permitted. Participants were verbally encouraged for maximal possible effort 
throughout the testing. A member of the research team tallied the number of laps completed to 
the nearest 5yd. Final distances were converted to meters upon completion.   
Cardiopulmonary Exercise Test (CPET) 
Participants were required to familiarize with the electronically braked cycle ergometer 
and mask used for the CPET at the end of day one. Participants completed an identical protocol to 
the maximal test, including the strength progression and use of the Borg RPE scale, but were 
stopped at ~75% of their heart rate reserve (HRR) on day one. The maximal CPET was completed 
on day two and is described in detail below.  
On day two, study participants were fitted with the oxygen sensor on the right thigh and 
rested for 5-10 minutes before being fitted with the mask on the bike. Participants began sitting 
quietly on the cycle ergometer for 3-minutes while the researchers collected resting metabolic data. 
The first stage of the test began as a 2-minute unloaded warm up at 0 watts followed by a 3-minute 
loaded warm up phase of 20 watts. Following the warm up stages, the wattage/workload increased 
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continuously by 15watts/min until test termination. Termination of the test was determined by 
subject reaching volitional exhaustion and signaling to stop the test, VO2 plateau or decrease with 
increase in exercise intensity, or an abnormal subject response to the test was observed and 
therefore the research team terminated the test (however, did not occur). This protocol has been 
previously successfully implemented in other clinical populations (Wilkerson et al., 2011). Heart 
rate and RPE were continually monitored and recorded throughout the testing. Blood lactate was 
collected by fingertip puncture 3-minutes after the completion of the maximal CPET. 
Get REAL & Heel Exercise Intervention 
 Following testing, participants completed exercise training 3 days/week for 16 weeks at 
the UNC GRH Exercise Facility. Exercise was a combination of both strength and strength 
exercise and was designed to progressively increase to a moderate-high workload but adapted to 
each participant as necessary. Aerobic exercise included a variety of options including walking, 
cycling, elliptical, etc. For the first 2 weeks of exercise training, exercise volume and intensities 
began at 10-15 minutes at low intensity of 50-60% of the participant’s heart rate reserve (HRR) 
with a corresponding RPE between 8-11. For participants who were deconditioned, exercise 
duration may have been reduced by 5-10 minutes. The goal was for participants to achieve 30 
minutes of moderate intensity aerobic exercise by mid to end of the 16-week program using 65-
75% HRR with a respective RPE between 12-14 (Table 2).  
Table 2. Progression of aerobic training exercise prescription. 






• Stationary bike 
• Elliptical 
• Stepper 
Duration (min) 10-15 10-30 30 
Intensity Low Moderate 
RPE 8-11 12-14 
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 Strength exercises targeted large muscle groups in the upper body, lower body, and core to 
improve strength, balance, and functionality. Each session of strength training lasted 
approximately 30 minutes. Two sets of each exercise were performed for 10-15 repetitions with 
intensity progressing in weeks 1-5 from light to moderate (RPE 7-13). After week 5, attempts were 
made to increase the intensity from moderate to high (RPE 14-15) for 2 sets of 10 repetitions of 
each exercise.  Exercises targeting major muscles groups included: lateral raises wall push-ups, 
rows, squats, bridge, plank, reverse sit up, shrugs, tandem stance, and lateral pulldown. 
Modifications to these exercises were made for any existing injuries, orthopedic limitations, or 
sequela from anti-cancer treatments (Table 3). 
Table 3. Progression of strength training exercise prescription. 





• Body weight 
• Resistance bands 
• Machine 
• Dumbbells 
Duration (min) 30 
Intensity Light to moderate High 
RPE 7-13 14-15 
Sets x Reps / exercise 1x15 2x10-15 2x10 
 
 Training progression was accomplished slowly, starting with 1 set of strength exercises 
using no weight or very light weight in the first two weeks of training with the number of 
repetitions achieving 15, then increased based on the participant’s ability and limitations up to 2 
sets during weeks 3-5 of training. As participants progressed to tolerate increased resistance, a 
balance component was carefully added to the training regimen. This included performing strength 
exercises with a level of complexity that challenged postural control.  
All exercise training sessions was recorded in a participant log stored in a locked filing 
cabinet at GRH. This log contained information about the time, mode, amount and intensity of 
exercise completed per session and the corresponding RPE’s. With safety as the utmost priority, 
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all participants were continuously monitored and supervised during all phases of the exercise 
sessions at GRH. 
 Participant adherence and compliance were quantified using exercise logs to determine the 
exercise dose completed over 16-weeks. Adherence reflects attendance (ATT), simply the number 
of days participants came to the GRH facility out of the total days possible in 16 weeks (48 days 
total). Aerobic compliance (aCOMP) was calculated as the number of days (out of 48) where 
participants completed ≥80% of the prescribed duration at the prescribed intensity. Strength 
compliance (sCOMP) was calculated as the number of days (out of 48) where participants 
completed ≥80% of the prescribed volume (sets x reps) at the prescribed intensity. 
Sample Size Estimate 
Sample size estimates were calculated a priori and were based on the primary outcome of 
aerobic capacity. Arterial stiffness analysis was evaluated for power post hoc. Published 
systematic reviews and meta analyses support exercise therapy to increase aerobic capacity in 
breast cancer survivors by approximately 2.3 - 2.8 mL/kg/min (Battaglini et al., 2014b; J M Scott 
et al., 2018). We opted for a change of 2.5mL/kg/min. The sample size required was 26 total 
participants using magnitude-based inferences, but oversampling was performed to account for 
potential dropouts and missing data. 
Statistical Analysis  
Statistical analyses were performed using Statistical Package for Social Sciences (SPSS) 
version 25.0 (IBM, Armonk, NY) and jamovi open source computer software (The jamovi 
project, version 1.2.5) . Baseline descriptive statistics (means (SD); percentages for categorical 
variables) were computed to summarize participant demographics and breast cancer 
diagnosis/treatment characteristics at baseline and to summarize participant attendance and 
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compliance with the exercise intervention. Independent t-tests were used to compare groups at 
baseline, and to compare exercise attendance and compliance following training. Cohen’s d was 
calculated for exercise attendance and compliance measures, using the difference between the 
outcome means for the BCS and CTL groups divided by the pooled SD. For interpretation of 
effect sizes, Cohen’s “rules of thumb” were used: small=0.20, medium=0.50, and large=0.80 
(Cohen, 1977).  
Because the purpose of this study was also to evaluate the impact of community-based 
exercise training on arterial stiffness and aerobic capacity, univariate linear regression models 
were used to evaluate associations of pre-post change in PWV (deltaPWV, adjusted for MAP) 
and pre-post change in VO2peak (delta VO2peak, adjusted for age) with days since end of treatment 
(EOT), days of exercise attendance (ATT), days of aerobic exercise compliance (aCOMP), and 
days of strength exercise compliance (sCOMP) in the BCS group. For exploratory purposes, 
univariate analyses were then repeated using the pooled sample (BCS plus CTL).  Due to sample 
size limitations, multivariable analyses were not conducted. 
 
Aim 1: To determine the cardiovascular profile of breast cancer survivors compared to women 
without a cancer history before and after a 16-week, community-based exercise program. 
Null Hypothesis 1a: PWV will not differ between BCS and CTL at baseline. 
Null Hypothesis 1b: Changes in PWV of BCS and CTL will not differ between following 
participation in community based, exercise training.  
For Hypothesis 1a, a linear mixed model was used to assess the effects of time (pre vs. 
post) and group (BCS vs. CTL) on PWV. Models used fixed effects of time and group and a 
random effect of subject with adjustment for mean arterial pressure (MAP). The α-level was set a 
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priori for all statistical procedures at < 0.05. If time-by-group interactions were not significant, 
the final models estimated the main effects of group and time. 
 
Aim 2: To determine the aerobic capacity of breast cancer survivors compared to women 
without a cancer history before and after a 16-week, community-based exercise program. 
Null Hypothesis 2a: VO2peak will not differ in BCS than CTL at baseline. 
Null Hypothesis 2b: Changes in VO2peak of BCS and CTL will not differ following 
participation in community based, exercise training.  
For Hypothesis 2a, a linear mixed model was used to evaluate the effects of time (pre vs. 
post) and group (BCS vs. CTL) on VO2peak. Models used fixed effects of time and group and a 
random effect of subject with adjustment for age. The α-level was set a priori for all statistical 
procedures at < 0.05. If time-by-group interactions were not significant, the final models 
estimated the main effects of group and time. 
 
Exploratory Aim 1: To determine the relationship between baseline cardiovascular variables 
(PWV, AIx, Buckberg Index) with changes in aerobic capacity (DVO2peak) in breast cancer 
survivors and women without a cancer history.  
 
Exploratory Aim 2: To determine the relationship between baseline cardiovascular variables 
(PWV, AIx, Buckberg Index) with training response (responders (DVO2peak ≥ 2.5ml/kg/min) vs. 
non-responders (DVO2peak < 2.5ml/kg/min)) in breast cancer survivors and women without a 
cancer history.  
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Exploratory Aim 3: To determine the relationship between baseline p16INK4a and 
clinical/functional patient outcomes including but not limited to DVO2peak, arterial stiffness, 
6MWT, and lean body mass. 
 
Due to the exploratory nature of Exploratory Aim 1, 2, and 3, no specific hypotheses were tested. 
Exploratory aims were assessed using univariate linear regression analyses to determine the 












With ever-increasing survival rates among women with early breast cancer (DeSantis et 
al., 2019), the risk of dying from cardiovascular disease (CVD) exceeds that of dying from breast 
cancer (Armenian et al., 2017; Patnaik et al., 2011; Sturgeon et al., 2019).  Cardiac-specific 
damage is well recognized and congestive heart failure is the most concerning cardiovascular 
risk for BCS, especially those treated with anthracycline chemotherapy (Henriksen, 2018; Jain et 
al., 2017). Heart failure can be assessed using echocardiograms to detect changes in resting left 
ventricular ejection fraction (LVEF) (Felker et al., 2000) and while not a standardized practice, is 
typically monitored during treatment or when survivors become symptomatic, which can be 
years beyond diagnosis (Armenian et al., 2017; Jain et al., 2017; Schmitz et al., 2012). Therefore, 
cardiac monitoring and evaluation may be logistically challenging to coordinate. There is also 
concern that ventricular dysfunction may not be detected at rest (standard testing procedure) but, 
instead, only when the cardiovascular system is taxed with exercise (Beaudry et al., 2019, 2018; 
Foulkes et al., 2019; Koelwyn et al., 2016, 2016).  Deterioration in cardiac performance may 
therefore be unintentionally missed until overt enough to induce noticeable changes at rest, 
which is likely indicative of permanent damage.  
Alternative to cardiac-specific damage and less studied to date, substantial vascular-
specific damage has been detected in BCS with even low to moderate doses of cardiotoxic 
cancer therapies and within the first year of survivorship, long before heart failure may develop 
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(Chaosuwannakit et al., 2010; Didier et al., 2017; Drafts et al., 2013; Ederer et al., 2016; Grover 
et al., 2015; Jain et al., 2017; Mulrooney et al., 2012). Precisely how the heart is damaged by 
cancer therapies is a topic of on-going research but vascular-specific changes may occur 
upstream of cardiac-specific damage (Khouri et al., 2012; A. F. Yu & Jones, 2016; Zagar, 
Cardinale, & Marks, 2016). Cardiac tissue is perfused by the aorta and coronary arteries; 
therefore, one hypothesis is that cancer treatments may cause acute stiffening of central vascular 
structures. This, in turn, may increase afterload on the heart and damage cardiac tissue, which 
may lead to ventricular dysfunction, heart failure, and/or overall CV fitness decline (L. W. Jones, 
Courneya, et al., 2012; Laurent et al., 2006). Therefore, vascular health decline may be an early 
clinical sign of impending CV damage or increased CV risk, but there is a paucity of data related 
to vascular health profiles of BCS and more work is needed (Armenian et al., 2017; Erbel et al., 
2014; Mehta et al., 2018; Mozos et al., 2017).   
Fortunately, valid and non-invasive techniques, such as pulse wave velocity (PWV) and 
pulse wave analysis (PWA), are available to ascertain vascular health status (Gotzmann et al., 
2019; Laurent et al., 2006; Milan et al., 2019; Nakagomi, Shoji, Okada, Ohno, & Kobayashi, 
2018). Carotid femoral PWV (cfPWV) is the gold standard to evaluate central arterial stiffness 
and is captured via arterial tonometry (applied pressure sensor) (Laurent et al., 2001, 2003) and 
PWA provides measures of other hemodynamic variables related to central and peripheral blood 
pressure, pulse pressure wave reflections, and an index of myocardial oxygen (J. I. Davies & 
Struthers, 2003; Kim & Braam, 2013) .Two 2010 meta-analyses demonstrated the prognostic 
value of arterial stiffness and central pressures as independent predictors of future CV events and 
all-cause mortality in some clinical populations and in the general population, but have yet to be 
extensively studied in clinical oncology (L M Jones et al., 2013; Lynnette M Jones, Stoner, 
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Brown, Baldi, & McLaren, 2019; Vlachopoulos, Aznaouridis, O’Rourke, et al., 2010; 
Vlachopoulos, Aznaouridis, & Stefanadis, 2010a).  
Of the limited existing data in oncology patients, treatment with anthracycline 
chemotherapy and radiation have been associated with increased arterial stiffness (Mozos et al., 
2017). Fortunately, two studies suggest aortic stiffness may normalize or recover years after 
cancer chemotherapy, but further research is needed to evaluate factors that may contribute to 
this recovery process or prevent initial decline in cancer survivors.  (Grover et al., 2015; 
Koelwyn et al., 2016). Exercise is a known promoter of CV health in the general population, has 
shown promise to improve arterial stiffness in patients with coronary artery disease, and may be 
beneficial to BCS vascular health following chemotherapy (D J Green et al., 2011, 2012; Daniel 
J Green & Smith, 2018; Oliveira, Ribeiro, Alves, Campos, & Oliveira, 2014). In one study 
evaluating cardiac and vascular health in long-term BCS, no difference was found between 
survivor and control groups; however, both groups self-reported substantial exercise engagement 
(about 55 minutes/day) (Koelwyn et al., 2016). To our knowledge, only one study has evaluated 
the impact of exercise training on arterial stiffness in BCS and found significant improvement in 
aortic PWV following 12 weeks of circuit training (Lynnette M Jones, Stoner, Baldi, & 
McLaren, 2020). However, in the two previously mentioned studies, survivors were 
approximately 7 years post treatment completion (Lynnette M Jones et al., 2020; Koelwyn et al., 
2016). The impact of exercise training on vascular health acutely following treatment completion 
(within ~1-2 years) has yet to be explored.  
Research evaluating the vascular health profile and the potential benefit of interventions 
such as exercise on vascular outcomes in women with breast cancer would further our 
understanding of vulnerable components of the cardiovascular cascade in this population 
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(Lynnette M Jones et al., 2019; J M Scott et al., 2016). Advances in this area of research may 
also generate improved CV monitoring and management strategies clinicians can use in the 
future to optimize patient-centered care. The current study aimed to profile the cardiovascular 
system of women with early breast cancer who have recently completed primary cancer 
treatment, and to evaluate the impact of a 16-week community-based exercise training program 
on arterial stiffness compared to an age-matched control group of women who are cancer-free. 
Methods 
Study Overview 
In this non-randomized study, two groups of women (one BCS, one non-cancer controls) 
of similar age and activity level were recruited (Figure 1). Women completed two days of 
exercise testing (pre) in a research laboratory and then asked to complete 16-weeks of exercise 
training at a local community-based program before repeating exercise testing (post).  The study 
was approved by the Protocol Review Committee of the University of North Carolina (UNC) 
Lineberger Comprehensive Cancer Center and the Institutional Review Board at UNC Chapel 
Hill. All participants provided written informed consent. 
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Figure 1 Recruitment and retention 
 
Study Participants 
Breast cancer survivors had been diagnosed with early-stage (0-III) breast cancer and 
were within one year of completing primary therapy (chemotherapy, radiation, surgery). 
Participants in the CTL group were age-matched, did not have a history of cancer, and self-
reported they were physically active no more than 2 days per week. Both groups were free from 
overt cardiovascular, metabolic, or orthopedic limitations as reported by medical history 
questionnaire, and were cleared by cardiologists and oncologists (BCS only) prior to 
participating in the study. Participants in the BCS group were recruited from the Medical 
Oncology clinic at the North Carolina Cancer Hospital, and by word of mouth from local 
oncologists and cancer centers. Participants in the CTL group were residents from local cities 
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including Raleigh, Durham, Chapel Hill and surrounding areas recruited via electronic and paper 
fliers and word of mouth.  
Intervention 
For both groups, the 16-week intervention entailed supervised, progressive, aerobic and 
strength exercise training three days a week for approximately one hour per day (Table 1).  
Table 1 Exercise training progression at the Get REAL & Heel Exercise Program 






• Stationary bike 
• Elliptical 
• Stepper 
Duration (min) 10-15 10-30 30 
Intensity Low Moderate 
RPE 8-11 12-14 





• Body weight 
• Resistance bands 
• Machine 
• Dumbbells 
Duration (min) 30 
Intensity Light to moderate High 
RPE 7-13 14-15 
Sets x Reps / exercise 1x15 2x10-15 2x10 
 
The supervised training took place at the UNC Get REAL & Heel (GRH) Exercise Program for 
cancer survivors, an off-campus facility at a convenient location in the community. Participants 
were asked to maintain their current lifestyle habits outside of GRH training in order to best 
evaluate the program-specific effects. A variety of equipment for both aerobic and 
resistance/strength training has been used at GRH to adapt to individual participant fitness and 
mobility needs which allows trainers the ability to maximize patient safety and exercise 
engagement. For example, participants could choose treadmills, stationary bikes or ellipticals for 
aerobic work and dumbbells, resistance bands, or machine weights for strength training, 
depending on survivor ability and comfort. The specific prescription design is presented in Table 
1. Participants were encouraged to challenge themselves to safely engage at their prescribed 
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workloads, with increasing exercise intensity and duration/volume over time. The priority for 
training staff was to bring participants safely “up to speed” to attain weekly exercise goals 
reflective of current national guidelines (Campbell et al., 2019). 
Training records were maintained by exercise staff to track participant attendance and 
compliance over 16 weeks. Attendance (ATT) was calculated as the number of days participants 
came to the facility out of 48 total days of training opportunity. Aerobic compliance (aCOMP) 
was calculated as the number of days the participant achieved ≥80% of prescribed duration at the 
prescribed intensity using Borg Rating of Perceived Exertion (RPE) (Borg, 1973). Strength 
compliance (sCOMP) was calculated as the number of days the participants achieved ≥80% of 
prescribed strength volume (sets x repetitions) at the prescribed intensity using Borg RPE (Borg, 
1973). 
Overview of Procedures 
All study participants completed laboratory visits prior to (pre-test) and immediately 
following (post-test) the 16-week exercise intervention. Both laboratory visits were conducted in 
the Exercise Oncology Research Laboratory (EORL) of the UNC Department of Exercise and 
Sport Science. These measures were collected after approximately 15 minutes of supine, fasted 
rest using the SphygmorCor XCEL device (AtCor Medical, Sydney, Australia) via brachial 
pressure cuff-based technique on limbs on the non-surgical side of BCS and on left side for 
CTLs following standard manufacturer guidelines and protocols. Measures and methods for 








Table 2 Study Measures and Equipment 
Variable (Equipment used) Explanation 
Whole Body Densitometry 
(Dual X-Ray Absorptiometer, DXA) 
Body composition 
• Normal Body Fat for females ≥50y ~16-25% (Jeukendrup & 
Gleeson, 2018) 
• Higher values generally indicative of poorer health similar to 
BMI but unlike BMI, distinguishes body composition (fat 
mass, fat free mass) 
Carotid-Femoral Pulse Wave 
Velocity (m/s) 
(Sphygmacor XCEL)  
• Gold standard technique for arterial stiffness, independent 
predictor of cardiovascular risk and mortality (Laurent et al., 
2001, 2006; Vlachopoulos, Aznaouridis, & Stefanadis, 2010a)  
• Lower values desired as indicative of better vascular 
compliance 
• Mean PWV ~8 m/s at <50 ys old (Mitchell et al., 2010; 
(Reference Values for Arterial Stiffness, 2010)), increases 
linearly with aging: ~6-8%/decade 
• 1m/s change considered clinically relevant (Guerin et al., 
2001; Vlachopoulos, Aznaouridis, & Stefanadis, 2010a) 
• BCS treated with anthracycline therapy show increases in 
PWV by ~4m/s within first few months of survivorship 




1. Central (cSBP) and peripheral 
blood pressure (SBP, DBP) 
2. Mean Arterial Pressure (MAP) 
3. Augmentation Index (AIx) 
4. Buckberg (BUCK) Index and 
Double Product 
1. Central pressure (norms ~undefined) speculated as better 
predictors of CV risk than peripheral (norm ~120mmHg, 
increases with age) (McEniery, Cockcroft, Roman, Franklin, 
& Wilkinson, 2014) 
2. Indicator of perfusion pressure, norm: 70-100mmHg, 
minimum of 60mmHg required, excess of 100mmHg 
indicative of poorer vascular health (DeMers D, 2019) 
3. An index of pulse wave reflection, AIx describes the 
amplification of central systolic pressure due to systemic 
arterial stiffness. Therefore, lower values are desired. Derived 
from the brachial waveform using validated transfer 
function.(Butlin et al., 2013; Laurent et al., 2006; McEniery et 
al., 2005)   
4. Indices of myocardial oxygen supply and demand 
o Buckberg: Associated with functional performance and 
QOL. Pressure and time ratio reflect resting measure of 
myocardial oxygen supply and demand. Has been 
suggested heart failure patients are best managed when 
index is >150% (Mannion et al., 2017) 
o Double product: product of systolic blood pressure and 
pulse rate, index of myocardial oxygen consumption, 
predicted CV mortality in coronary artery disease 
patients. (Gobel, Norstrom, Nelson, Jorgensen, & Wang, 
1978) 
o Higher Buckberg index and lower double product desired 
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Carotid-femoral PWV: After supine for 15 minutes, a BP cuff was placed on the thigh in line 
with the femoral artery for calculation of PWV. Using a custom-built level caliper, path length 
was measured from the carotid artery on the same side as the thigh cuff to the top of the cuff. 
The caliper avoids body contours that may muddle path length and strictly measured the length 
of the descending aorta. A tonometer was placed on the carotid artery on the neck on the same 
side as the cuff, and PWV was collected when wave form and quality control were recognized by 
the SphygmoCor. All PWV measures (SphygmoCor XCEL; AtCor Medical, Itasca, Illinois) 
were collected in the supine position in duplicate (triplicate if >10% difference) and the closest 
two values averaged.  
Pulse wave analysis (PWA) was obtained by using oscillometric pressure waveforms 
(SphygmoCor XCEL AtCor Medical) recorded on the arm opposite the involved breast for BCS 
and right side for CTL using a brachial cuff following standard manufacturer guidelines. An 
aortic pressure waveform was generated from averaged heartbeat waveforms from SphygmoCor 
XCEL. Peripheral BP (systolic: SBP, diastolic: DBP) was measured and central BP (cSBP) was 
estimated using a generalized pressure transfer function of the brachial pressure waveform 
derived at the arm (Butlin et al., 2013). Augmentation index (AIx) is the augmentation pressure 
defined as the maximum systolic pressure minus the pressure at the inflection point. AIx is 
expressed as a percentage of central pulse pressure and is a validated estimation of augmented 
cardiac pressure analogous to afterload due to the summation of outgoing and returning arterial 
wave reflections during systole (Laurent et al., 2006). Buckberg index and double product are 
indicators of myocardial oxygen supply and demand derived from blood pressure and time 
integrals (Hoffman & Buckberg, 2014). Buckberg is calculated as the diastolic to systolic 
pressure-time integral ratio and double product is central systolic blood pressure times pulse rate.  
 65 
Patient demographics and cancer-specific clinical data were extracted from the electronic 
medical record (EMR) by a member of the research team. 
Power Calculations 
This study was part of a larger study powered on a different primary outcome. At the 
time of data collection, the effects of exercise training on PWV of BCS had not been 
investigated, though previous reports demonstrated 6.6m/s (~95%) increase in arterial stiffness in 
BCS following completion of chemotherapy (Chaosuwannakit et al., 2010) and changes of 1 m/s, 
have been considered clinically meaningful in other populations (Vlachopoulos, Aznaouridis, & 
Stefanadis, 2010b). Post hoc power analysis of our data using an alpha level of 0.05, 80% power 
and sample sizes of 27 and 10 revealed we were powered to detect an effect size of 1.06.  
Statistical Analysis 
Statistical analyses were performed using Statistical Package for Social Sciences (SPSS) 
version 25.0 (IBM, Armonk, NY) and jamovi open source computer software (The jamovi 
project, version 1.2.5) . Baseline descriptive statistics (means (SD); percentages for categorical 
variables) were computed to summarize participant demographics and breast cancer 
diagnosis/treatment characteristics at baseline (Table 3) and to summarize participant attendance 
and compliance with the exercise intervention (Table 6). Independent samples t-tests were used 
to compare groups at baseline, and to compare exercise attendance and compliance following 
training. Cohen’s d was calculated for exercise attendance and compliance measures, using the 
difference between the outcome means for the BCS and CTL groups divided by the pooled SD. 
For interpretation of effect sizes, Cohen’s “rules of thumb” were used: small=0.20, 
medium=0.50, and large=0.80 (Cohen, 1977).  
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Three linear mixed models were assessed in this study. The first evaluated the effects of 
time (pre vs. post) and group (BCS vs. CTL) on PWV, SBP, DBP, MAP, HR, AIx, cSBP, 
BUCK, and central double product (Table 5). The second evaluated the effects of time (pre vs. 
post) and cancer treatment group (BCS with chemo vs. BCS without chemo; BCS with radiation 
vs. BCS without radiation (Table 6). The third assessed the effects of time (pre vs. post) and 
group by menopausal status (premenopausal BCS vs. postmenopausal BCS) on PWV (Table 6). 
All models used fixed effects of time and group and a random effect of subject with adjustment 
for MAP (PWV only). The third model also accounted for age. The a-level was set a priori for all 
statistical procedures at < 0.05. If all time-by-group interactions were not significant, final 
models estimated the main effects of group and time on all outcomes. 
Because the purpose of this study was to evaluate the impact of community-based 
exercise training on arterial stiffness, univariate linear regression models were used to evaluate 
associations of pre-post change in PWV (deltaPWV) with days since end of treatment (EOT), 
days of exercise attendance (ATT), days of aerobic exercise compliance (aCOMP), and days of 
strength exercise compliance (sCOMP) in the BCS group (Table 8). For exploratory purposes, 
univariate analyses were then repeated using the pooled sample (BCS plus CTL) (Table 9).  Due 
to sample size limitations, multivariable analyses were not conducted. 
Results 
Thirty-five women with breast cancer were enrolled, of which 32 completed all pre and 
post testing and 27 had successful pre and post PWV readings. Twenty-one non-cancer control 
women were enrolled, of which 15 completed all pre and post testing and 10 had successful pre 
and post PWV readings. Reliable PWV reading could not be detected in a few of the participants 
(BCS n=5; CTL n=5) due to anatomical thickness around the neck preventing a clear pulse wave 
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signal, which decreased our sample size. Those excluded were otherwise very similar to women 
with complete data. The final sample of 27 BCS and 10 CTL with complete data was analyzed 
for the current study (Figure 1). There were no differences at baseline between the two groups 
for demographic or clinical outcome variables (Table 3). Based on power analysis calculations, 
the interpretation of our findings should be approached as strictly preliminary. 
 










Demographics     
Age (yr) 54 (11) 53 (12) 56 (9) 0.434 
Height (cm) 166 (7) 167 (7) 163 (7) 0.146 
Weight (kg) 73 (10) 74 (10) 71 (10) 0.481 
BMI Categories (kg/m2)     
Normal (18.5 to <25) 
Overweight (25 to <30) 
Obese I (30 to <35) 

















Body Fat (%) 40 (5) 40 (6) 40 (6) 0.625 
Lean mass (kg) 41 (5) 41 (5) 40 (5) 0.657 
Postmenopausal (%) 62 59 70 0.710 
Race (Caucasian, %) 92 88 100 0.548 
Clinical Variables     
Pulse Wave Velocity (m/s) 7.7 (1.1) 7.7 (1.1) 7.7 (1.2) 0.936 
Resting heart rate (bpm) 66 (10) 67 (10) 63 (11) 0.365 
Central Systolic Blood Pressure (mmHg) 116 (11) 115 (11) 118 (9) 0.584 
Systolic Blood Pressure (mmHg) 126 (11) 125 (11) 128 (9) 0.596 
Diastolic Blood Pressure (mmHg) 79 (7) 79 (7) 79 (5) 0.980 
Mean Arterial Pressure (mmHg) 94 (8) 93 (9) 94 (5) 0.855 
Augmentation Index (%) 27 (10) 27 (11) 28 (7) 0.658 
Buckberg Index (SEVR) 145 (21) 145 (22) 144 (20) 0.873 
Double Product (mmHg*bpm) 7607 (1319) 7687 (1377) 7392 (1188) 0.553 














Hormone Receptor Status 
Positive 
  
81%   
HER-2 Status 
Positive (all received Trastuzumab) 
  








Time Since End of Treatment 
<3 months 
3 to <6 months 
6 to <9 months 

































Both BCS and CTL groups had the same mean number of training sessions (34 days of 
48 planned, p=0.938) for an average attendance rate of 71% (Table 4). Differences in aerobic 
compliance between groups did not reach statistical significance but demonstrated a medium to 
large effect size (Cohen’s d = 0.60), with CTL’s having a greater number of compliant days than 
BCS (32(10) vs 26(9) days). CTL participants also completed a greater number of days of 
strength training compared to BCS (18(3) vs 14(5), Cohen’s d = -0.83, p=0.031); albeit 
compliance with strength protocol was less than 40% in both groups.  
 









Effect Size p-value 
Intervention Attendance (days) 
Aerobic Compliance (days)  















For BCS and CTL, there were no significant time x group interactions for PWV (Figure 2) or any 
other hemodynamic variables included in analysis, nor any significant main effects of time or 
group (Table 5).  
Table 5 Results from linear mixed model of cardiovascular outcomes after 16-weeks of 
community-based exercise training in breast cancer survivors and non-cancer controls 
  Mean (SD)    









125 (7.1) 0.812 0.436 0.068 




78.3 (3.9) 0.582 0.635 0.164 












64 (11) 0.671 0.501 0.964 




29.4 (7.2) 0.390 0.345 0.951 




116 (6.3) 0.687 0.372 0.078 













7358 (1140) 0.585 0.761 0.471 
+ adjusted for mean arterial pressure (MAP). Data represented as means (SD). BCS, breast cancer 
survivors, n=27; CTL, controls, n =10; PWV, pulse wave velocity; BMI, body mass index; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate; AIx, 




Figure 2 Arterial stiffness at baseline and following 16-weeks of community-based exercise 
(mean(SE) using estimated marginal means from MAP-adjusted linear mixed model). 
 
Sensitivity analyses revealed no time x group interactions for PWV (Table 6) for either of the 
breast cancer treatment analyses or for menopausal status. A significant main effect for time 
demonstrated PWV in BCS significantly increased by 0.4m/s at post-test (95% CI [0.103, 0.781]; 
p=0.016) regardless chemotherapy status. For the radiation analysis, a significant main effect for 
group revealed PWV was higher at pre and post testing in women who received radiation (0.93 
m/s; 95% CI [0.257, 1.607]; p=0.012) than those who did not, but a significant main effect for 
time showed both groups of survivors increased arterial stiffness by 0.6m/s (95% CI [0.200, 
0.169]; p<0.01) after exercise training. Changes in arterial stiffness between pre and 
postmenopausal women were non-significant but demonstrated a medium effect size (Cohen’s 
D= -0.46). 
 
Table 6 Results from linear mixed model of pulse wave velocity after 16-weeks of community-
based exercise training in BCS with differing treatment regimens 
    Mean (SE)        









8.0 (0.3) -0.33 0.495 0.692 0.016 




7.5 (0.3) -0.45 0.266 0.012 0.009 




8.2 (0.3) 0.45 0.079 0.576 0.055 
*Adjusted for MAP and age. ^calculated using change scores 
Data represented as estimated marginal means (SE) from MAP-adjusted linear mixed model. PWV, pulse 
wave velocity; BCS, breast cancer survivors; C, chemotherapy; R, radiation; BCS+C n=16 , BCS-C n=11; 
BCS+R n=21, BCS-R n=6; Premeno n=11 ; Postmeno n=16 .Bold indicates P value < 0.05. 
 
We found no significant univariate associations between change in PWV (deltaPWV) and 
independent variables in the BCS group. Based on the similarity in cardiovascular profiles 
between groups, the dataset was pooled for exploratory univariate analysis and revealed 
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significant associations between deltaPWV and aCOMP (R=-0.343, ß= -0.029, p=0.038) (Table 
7).  
 
Table 7 Independent associations of change in pulse wave velocity (deltaPWV*) with baseline 
clinical measures and exercise engagement measures in the pooled sample (n=37) 
 Univariate 





ATT^ -0.029 -0.003 -0.0351 0.0296 0.863 
aCOMP^ -0.343 -0.029 -0.0564 -0.002 0.038 
sCOMP^ -0.207 -0.0352 -0.0924 0.0219 0.219 
Footnote: ATT=days of attendance to exercise intervention, aCOMP=days of aerobic exercise compliance, sCOMP= 
days of strength exercise compliance   
^=higher values desired 
*=lower values desired 
 
While exploratory yet interesting, when graphed, relatively consistent improvement in arterial 
stiffness appears to occur following approximately 35 out of 48 days of aerobic compliant 
training (Figure 3). Six out of 11 (55%) participants had decreased PWV (3 (50%) of which were 
BCS), 3 (27%) were relatively unchanged, and 2 (18%) appeared to increase after 35 days 


















Figure 3: Pre-post intervention change in PWV (deltaPWV, m/s) per days of aerobic exercise 
compliance using pooled data (n=37).  
 
* = Denotes potential threshold for minimum number of days of aerobic compliance that appear to result in 
generally improved PWV 
 
Discussion 
Data, while limited, support arterial stiffness increases (>1m/s) during the first year of 
survivorship in BCS treated with cardiotoxic chemotherapy compared to non-cancer controls, 
and it is possible this deterioration in vascular-specific health may be a contributing factor to the 
increased cardiovascular risk profile of women with breast cancer (Chaosuwannakit et al., 2010; 
Drafts et al., 2013; L M Jones et al., 2013; Mulrooney et al., 2012). Arterial stiffness profile of 
patients treated with non-anthracycline therapies is not known. Two published studies support a 
potential beneficial role of exercise for vascular health in BCS but evaluated participants who 
were ~7 years post treatment (Lynnette M Jones et al., 2020; Koelwyn et al., 2016). 
Interestingly, in our study, baseline PWV for both BCS and CTL were lower compared to 
previous work (Chaosuwannakit et al., 2010; Drafts et al., 2013), lower than published reference 
values for non-cancer populations of similar age (Reference Values for Arterial Stiffness, 2010), 
and did not change following 16-weeks of exercise training when compared to CTL. However, 
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when evaluating changes in arterial stiffness in BCS only, significant increases in arterial 
stiffness were observed from pre to post testing regardless if women received chemotherapy 
(p=0.016) or radiation (p<0.01). Only two women in our BCS sample did not receive 
chemotherapy or radiation. Women treated with radiation also had greater arterial stiffness at 
pre-testing (1.15m/s, 95% CI [0.351, 1.95], p<0.01) than women who were radiation naïve. 
Regardless the absolute values of arterial stiffness at post-test still fall within healthy ranges, the 
change trajectory is not in a desired direction. Based on our findings in this exploratory subset 
analysis of BCS, chemotherapy and radiation may predispose survivors to increased arterial 
stiffness, and the impact of exercise on this change also warrants further investigation.  
Based on our findings, progressive intensity exercise training may have little effect on 
arterial stiffness when comparing the cancer and non-cancer groups. It is possible that the 
exercise intervention may have prevented dramatic increases in arterial stiffness of our BCS like 
those observed in previously published cancer studies over similar time periods 
(Chaosuwannakit et al., 2010; Drafts et al., 2013). However, arterial stiffness still increased in 
BCS when evaluated independently, and it is not clear if this was influenced by cancer therapy 
alone, exercise participation, or both. This is difficult to resolve without a non-exercising breast 
cancer survivor group for comparison. Based on the cardiovascular measures collected in this 
study, our entire group of participants reflected healthy profiles which was somewhat 
unexpected, but the trajectory of change in arterial stiffness in an undesired direction 
(Chaosuwannakit et al., 2010; Drafts et al., 2013; Mulrooney et al., 2012). One question is 
whether the relatively healthy profile of our BCS will deteriorate over time similar to 
anthracycline-treated patients in pioneering publications (Chaosuwannakit et al., 2010; Drafts et 
al., 2013) or due menopausal changes (Yersal et al., 2018; Zagar et al., 2016) (as a medium 
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effect was observed for changes in PWV between our pre and postmenopausal BCS (Cohen’s 
d=0.45, p=0.576)), or will be maintained as observed in other recent studies (Lynnette M Jones 
et al., 2019). Less than 20% of our sample was treated with anthracycline chemotherapy, unlike 
the participants included in founding studies, but stiffening trajectories still appear evident 
(Chaosuwannakit et al., 2010; Drafts et al., 2013; Koelwyn et al., 2016). These preliminary 
findings and the influence of exercise on their change deserve further investigation but reiterate 
existing literature that radiation and chemotherapy may contribute unique cardiovascular risk in 
BCS (Jain et al., 2017; Rygiel, 2017; Jessica M Scott et al., 2018; Zagar et al., 2016).  
While exploratory, a very interesting finding of our study is the significant association 
between days of aerobic compliance and deltaPWV (R= -0.343, p=0.038) in the pooled dataset. 
We absolutely respect that a pooled dataset includes women with and without breast cancer, but 
this analysis was purely to explore potential associations between cardiovascular variables due to 
the nearly identical profile between BCS and CTL in this study. The significant relationship 
existed for aerobic compliance but not attendance (R=-0.029, p=0.863). Per the a priori 
definitions used in this study, compliance was innately dependent on attendance – one could not 
be compliant without attending a session. The lack of significant association between attendance 
and deltaPWV but the presence of a small but significant association between aerobic 
compliance and deltaPWV suggests exercise intensity may be a critical component when 
targeting vascular changes. These findings are congruent with results from a recent meta-analysis 
that supported aerobic exercise intensity as a significant correlate of improvements in arterial 
stiffness (Ashor et al., 2014). Exercise engagement at progressive intensity is something that is 
reasonably within an individual’s control and with ~12% of the variation in deltaPWV attributed 
to days of aerobic exercise compliance per results of our study (R2=0.117), the importance of 
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intensity should not be overlooked (Table 7). Furthermore, when presented graphically, (Figure 
3) there appears to be a potential threshold where days of aerobic compliance achieved begin to 
demonstrate relatively consistent reduction in PWV from pre to post intervention. Although 
highly preliminary at this time, in our study, ≥35 of 48 prescribed days of compliant aerobic 
exercise appears to provide the greatest benefit in terms of arterial stiffness. A potential caveat 
however is that arterial stiffening was still observed when evaluating BCS as an independent 
group. At this time, it cannot be determined if progressive intensity exercise is beneficial or 
potentially harmful to arterial health in BCS. For future research about interventions to promote 
CV health in women with breast cancer, exercise training programs with progressive aerobic 
exercise intensity need further investigation. As a pooled group, it appears aerobic exercise 
intensity may benefit arterial stiffness but in BCS alone, arterial stiffness increased following 
exercise training. The true impact of exercise on arterial health in BCS, most of who received 
chemotherapy or radiation, cannot be clearly determined in this study.  
Attendance, and compliance to exercise training programs are a well-recognized 
challenge in exercise oncology research (Amy A Kirkham et al., 2018; Neil-Sztramko, Winters-
Stone, Bland, & Campbell, 2019). Attendance in the current study was moderate and similar to 
that of previously published projects, but compliance to the intervention prescription was sub-
optimal (K S Courneya et al., 2007; Kerry S Courneya et al., 2013; Amy A Kirkham et al., 2018; 
van Waart et al., 2015). Based on the observations of our exercise staff and research team, 
participant compliance to training was primarily hindered by not reaching prescribed exercise 
intensity, as measured by self-reported RPE. This method has weakness of being a subjective 
measure; however, it is highly feasible in a community-based setting where heart rate monitors 
may be cumbersome and otherwise unrealistic. It was observed that while participants would and 
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could complete both prescribed duration (aerobic) and volume (sets x reps, strength) well, it was 
challenging for them to engage at prescribed intensity, especially in the second half of training 
when intensity targets increased. Strength training intensity was achieved less frequently than 
aerobic intensity for both groups, leading to fewer strength compliant days than aerobic (Table 
6), which has been observed previously in this population (Amy A Kirkham et al., 2018; 
Ottenbacher et al., 2015; Santos et al., 2019). Training staff encouraged participants to safely 
reach the more difficult intensities and no adverse events were documented during training; 
therefore, lack of training support, injury, or unnecessary discomfort were unlikely contributors 
to sub-optimal intensity compliance. However, if increased aerobic compliance has the potential 
to improve arterial stiffness, as suggested by our study, determining how to successfully engage 
participants at increasing intensities should remain a priority for the benefit of cardiovascular 
health. This is particularly important in the long term as arterial stiffening and cardiovascular 
risk naturally increase with age, and the latter especially so in BCS (Grover et al., 2015; 
McEniery et al., 2005; Patnaik et al., 2011; Vaitkevicius et al., 1993) 
The primary limitation of this study is that it is underpowered due to small sample size. Five 
participants in both the BCS and the CTL groups were not included in analysis due to inability to 
capture a clear pulse wave reading at pre-testing. Adiposity around the neck of these participants 
prevented detecting a clear signal and complicated the ability to capture vascular outcomes. 
Other techniques such as cuff-based capture instead of applanation tonometry for carotid pulse 
readings may be appropriate in individuals where higher body fat complicates readings. Another 
limitation of this study is self-selection as participants had to be relatively locally residing, 
willing, able, and interested in participating in a four-month training study. This may have 
unintentionally recruited “worried but well” survivors who may represent a slightly healthier 
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subsample compared to the general population of BC survivors. Participants were also mostly 
white and had the job and family flexibility to be able to participate in 3 day/week training. This 
profile may poorly represent the majority of survivors in the same time frame post primary 
cancer treatment and future work would benefit from the inclusion of more diverse participants.  
In conclusion, while preliminary, our overall clinical findings are reassuring that early stage 
breast cancer survivors treated primarily with non-anthracycline therapies have similar and 
healthy cardiovascular profiles as age-matched, non-cancer counterparts before and after 
exercise training. However, exploratory analyses revealed arterial stiffness of BCS does appear 
to increase in those treated with chemotherapy or radiation following exercise. The preliminary 
nature of this investigation prevents our ability to conclude if exercise is beneficial or harmful in 
this patient population and deserves additional attention for clarification. In the long term, 
improving our understanding of how arterial health of BCS changes naturally and in response to 
exercise training will enhance our ability to properly advise patients regarding strategies to 













Aerobic capacity reflects the ability to use oxygen to produce energy for physical work, 
is impaired in breast cancer survivors (BCS), and associated with all-cause mortality, morbidity 
and disease-specific mortality  (Blair et al., 1989; L. W. Jones, Hornsby, et al., 2012; L. W. Jones 
et al., 2010; Lakoski et al., 2013; A. B. Peel, Thomas, Dittus, Jones, & Lakoski, 2014; J. B. Peel 
et al., 2009). Aerobic capacity diminishes on average 5-10% during treatment but as much as 20-
30% by the end of treatment, which is the equivalent of approximately 10 years of age-related 
declines in VO2 (K S Courneya et al., 2007; L. W. Jones, Courneya, et al., 2012). A single 
metabolic equivalent (MET) increase in aerobic capacity (3.5 mL/kg/min) corresponds with 12-
15% reduction in all-cause mortality risk and increases in aerobic capacity are associated with 
reduced cardiovascular (CV) risk in cancer and non-cancer populations (Barlow et al., 2012; A A 
Kirkham et al., 2016; A A Kirkham & Davis, 2015; Kodama et al., 2009; Myers et al., 2002). 
This relationship is of particular importance in a patient population like BCS where CV disease 
is a leading cause of death (Patnaik et al., 2011). From a quality of life perspective, adequate 
aerobic capacity supports the ability to be physically functional and live independently which are 
critical components of long-term survivorship (Swartz et al., 2017). Therefore, maintaining or 
promoting aerobic capacity and physical function in survivorship is essential to breast cancer 
survivorship (Demark-Wahnefried, Morey, Sloane, Snyder, & Cohen, 2009). 
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Aerobic exercise has long been documented to improve aerobic capacity in non-cancer 
populations and is rapidly gaining appreciation in the exercise oncology arena (Battaglini et al., 
2014b; Campbell et al., 2019; Hayes, Newton, Spence, & Galvão, 2019; A A Kirkham et al., 
2016; Ozemek et al., 2018). In recent decades, the addition of resistance/strength training to 
aerobic exercise has increased and has proved beneficial for cancer survivors, especially in terms 
of muscular strength which is a well-recognized impairment in BCS (Battaglini et al., 2014b; 
Hanson, Wagoner, Anderson, & Battaglini, 2016). Multiple, well-designed and controlled 
exercise intervention trials have tested and demonstrated the beneficial impact of exercise on 
aerobic capacity in cancer survivors so that there is now strong evidence to support the 
recommendation of 2-3 days/week of moderate intensity aerobic and strength training exercise 
for approximately 12 weeks for improving physical function and aerobic capacity in cancer 
patients (Battaglini et al., 2014b; Campbell et al., 2019; McNeely et al., 2006). With the advent 
of increasingly specific exercise prescriptions, the translation of laboratory/research trial-based 
exercise interventions to “real-world” settings is now possible, but is yet to be well-studied. 
However, this is important to evaluate to establish potential effectiveness for survivors seeking 
exercise participation in practical venues (Amy A Kirkham et al., 2018).  
Community-based exercise programs may provide more flexible and hence feasible 
options for survivor access, accommodation, and enjoyment, with the trade-off of less control 
over exercise fidelity compared to a lab-based setting. Community-based programs have the 
potential to play an important role in breast cancer survivorship, however, further work is needed 
to determine the efficacy of “trial-proven” prescriptions delivered through these real world 
settings in an environment where the survivorship pool is growing (Bluethmann et al., 2016; 
Swartz et al., 2017). The purpose of this study was to evaluate the impact of the Get REAL & 
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Heel Cancer & Exercise Program (GRH) on aerobic capacity of BCS in and around Chapel Hill, 
North Carolina. This established program has served cancer survivors since 2006 through small 
group exercise training that is highly reflective of current national physical activity guidelines for 
cancer survivors (Campbell et al., 2019). The program includes progressive intensity aerobic and 
strength exercise training for cancer survivors, 3 days per week for a 16-week series. 
Methods 
Study Overview 
In this non-randomized study, two groups of women (one BCS, one non-cancer controls) 
of similar age and activity level were recruited (Figure 1). Women completed two days of 
exercise testing (pre) in a research laboratory and then asked to complete 16-weeks of exercise 
training at a local community-based program before repeating exercise testing (post).  The study 
was approved by the Protocol Review Committee of the University of North Carolina (UNC) 
Lineberger Comprehensive Cancer Center and the Institutional Review Board of the Department 
of Exercise and Sport Science and School of Medicine at UNC Chapel Hill. All participants 
provided written informed consent. 
 




Breast cancer survivors had been diagnosed with early-stage (0-III) breast cancer and 
were within one year of completing primary therapy (chemotherapy, radiation, surgery) but 
could still be on endocrine therapy. Participants in the CTL group were age matched, did not 
have a history of cancer, and self-reported they were physically active no more than 2 days per 
week. Both groups were free from overt cardiovascular, metabolic, or orthopaedic limitations, 
and were cleared by cardiologists and oncologists (BCS only) prior to participating in the study. 
Participants in the BCS group were recruited through the Medical Oncology clinic at the North 
Carolina Cancer Hospital, and by word of mouth through local oncologists and cancer centers. 
Participants in the CTL group were residents from local cities including Raleigh, Durham, 
Chapel Hill and surrounding areas recruited via electronic and paper fliers and word of mouth.  
Intervention 
For both groups, the 16-week intervention entailed supervised, progressive, aerobic and 
strength exercise training (Table 1) at the UNC Get REAL & Heel Exercise Program, three days 
a week for approximately one hour per day. Participants were asked to maintain their current 
lifestyle habits outside of GRH training in order to best evaluate the program-specific effects. A 
variety of training equipment for both aerobic and resistance/strength has been used at GRH to 
adapt to individual participant fitness and mobility needs which allows trainers the ability to 
maximize patient safety and exercise engagement. For example, participants could choose 
treadmills, stationary bikes or ellipticals for aerobic work and dumbbells, resistance bands, or 
machine weights for strength training, depending on survivor ability and comfort. The specific 
prescription design used in the program and this study is presented in Table 1. Participants were 
encouraged to challenge themselves to safely engage at their prescribed workloads, with 
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increasing exercise intensity and duration/volume over time. The priority for training staff was to 
bring participants safely “up to speed” to attain weekly exercise goals reflective of current 
national guidelines (Campbell et al., 2019). 
Table 1 Exercise progression in the Get REAL & Heel Exercise Program 






• Stationary bike 
• Elliptical 
• Stepper 
Duration (min) 10-15 10-30 30 
Intensity Low Moderate 
RPE 8-11 12-14 





• Body weight 
• Resistance bands 
• Machine 
• Dumbbells 
Duration (min) 30 
Intensity Light to moderate High 
RPE 7-13 14-15 
Sets x Reps / exercise 1x15 2x10-15 2x10 
 
Training records were used to track participant attendance and exercise compliance over 
16 weeks. Attendance was calculated as the number of days participants came to the GRH 
facility. Aerobic compliance (aCOMP) was calculated as the number of days the participant 
achieved ≥80% of prescribed duration at the prescribed intensity using Borg Rating of Percieved 
Exertion (RPE) (Borg, 1973). Strength compliance (sCOMP) was calculated as the number of 
days the participants achieved ≥80% of prescribed strength volume (sets x reps) at the prescribed 
intensity using Borg RPE (Borg, 1973). 
Overview of Procedures 
All study participants completed two laboratory visits prior to (pre-intervention) and 
immediately following (post-intervention) the 16-week exercise program. Both sets of laboratory 
visits were conducted in the Exercise Oncology Research Laboratory (EORL) of the UNC 
Department of Exercise and Sport Science. On day one, participants completed a fasted body 
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composition assessment using Dual X-ray Absorptiometry (DEXA, Hologic (Discovery W) 
followed by one 6-minute walk test (6MWT) and two timed up-and-go (TUG) tests, with the 
fastest time recorded for analysis. Participants then completed a familiarization session for the 
cardiopulmonary exercise (CPET) testing using a Lode electronically-braked cycle ergometer. 
Participants were fitted to the bike and equipped with a Polar telemetry system (Polar Electro 
Inc., Lake Success, NY) to monitor heart rate and a gas exchange mask to measure the fit and 
function of ParvoMedics metabolic system, albeit no gas was collected or analyzed during 
familiarization. Participants completed a 5-minute unloaded and 20W loaded warm-up followed 
by an incremental 15 watt/minute with protocol up to 75% heart rate reserve for familiarization. 
To minimize the potential impact of learning effects on maximal testing and because many 
participants were likely unfamiliar with maximal exercise testing, familiarization was designed 
as an opportunity for participants to experience the general progression of the test protocol, 
become familiar and fitted with the required equipment, and increase their likelihood to engage 
at a true maximal effort on the testing day.  
On day two, participants completed the same protocol but continued until they reached 
volitional exhaustion or were stopped when oxygen consumption plateaued despite increase in 
wattage, followed by lactate sampling at the fingertip 3 minutes post-test termination. Testing 
was also terminated if participants were unable to continue cycling exercising above 50rpm. Gas 
exchange was exported in five second average bins and peak oxygen consumption (VO2peak) was 
recorded as the average of the three highest recordings within the final minute of the maximal 
test. Time to test termination (TTE) was recorded as the ramp-only portion which excluded the 
5-minute warm up portion of the protocol, and peak wattage was the highest wattage recorded 
before test termination.  Patient demographics and cancer-specific clinical data were extracted 
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from the UNC Health Care electronic medical record (EMR) by a member of the research team. 
Power Calculations 
Sample size estimates were calculated a priori and were based on the primary outcome, 
aerobic capacity. Published systematic reviews and meta analyses support exercise therapy to 
increase aerobic capacity in breast cancer survivors by approximately 2.3 - 2.8 mL/kg/min 
(Battaglini et al., 2014b; J M Scott et al., 2018). We opted for a change of 2.5mL/kg/min. The 
sample size required was 26 BCS and CTL participants total using magnitude-based inferences, 
but oversampling was performed to account for potential dropouts and missing data. 
Statistical Analysis 
Statistical analyses were performed using Statistical Package for Social Sciences (SPSS) 
version 25.0 (IBM, Armonk, NY) and jamovi open source computer software (The jamovi 
project, version 1.2.5) . Baseline descriptive statistics (means (SD); percentages for categorical 
variables) were computed to summarize participant demographics and breast cancer 
diagnosis/treatment characteristics at baseline (Table 2) and to summarize participant attendance 
and compliance with the exercise intervention (Table 3). Independent t-tests were used to 
compare groups at baseline, and to compare exercise attendance and compliance following 
training. Cohen’s d was calculated for exercise attendance and compliance measures, using the 
difference between the outcome means for the BCS and CTL groups divided by the average 
pooled SD. For interpretation of effect sizes, Cohen’s “rules of thumb” were used: small=0.20, 
medium=0.50, and large=0.80 (Cohen, 1977) .  
Two linear mixed models were assessed in this study. The first evaluated the effects of 
time (pre vs. post) and group (BCS vs. CTL) on VO2peak, BMI, body fat, peak power, relative 
peak power, peak RPE, peak HR, peak lactate, 6MWT, and TUG (Table 4). The second 
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evaluated the effects of time (pre vs. post) and cancer treatment group (BCS with chemo vs. BCS 
without chemo) on VO2peak (Table 5). Both models used fixed effects of time and condition and a 
random effect of subject with adjustment for age. The a-level was set a priori for all statistical 
procedures at < 0.05. If time-by-condition interactions were not significant, the final models 
estimated the main effects of condition and time on all outcomes. 
Because the purpose of this study was to evaluate the impact of community-based 
exercise training on aerobic capacity, univariate linear regression models were used to evaluate 
associations of pre-post change in VO2peak (deltaVO2peak, adjusted for age) with days since end of 
treatment (EOT), days of exercise attendance (ATT), days of aerobic exercise compliance 
(aCOMP), and days of strength exercise compliance (sCOMP) in the BCS group (Table 6). For 
exploratory purposes, univariate analyses were then repeated using the pooled sample (BCS plus 
CTL) (Table 7).  Due to sample size limitations, multivariable analyses were not conducted. 
Results 
 
Thirty-five women with breast cancer were enrolled, of which 32 completed all pre and 
post intervention testing. Twenty-one non-cancer controls were enrolled, of which 15 completed 
all pre and post testing (Figure 1). Those who did not complete post testing were excluded due to 
missing data but otherwise very similar to women with complete data. At baseline (Table 2), 
groups differed by height (p=0.035), peak RPE (p=0.028), peak lactate (p=0.030), and TUG 
performance (p<0.01) but no differences were observed for aerobic capacity (VO2peak 








Table 2 Baseline Characteristics of Breast Cancer and Control Groups presented as mean (SD) 






Demographics     
Age (yr) 54 (11) 54 (12) 55 (8) 0.830 
Height (cm) 165 (8) 167 (7) 162 (7) 0.035 
Weight (kg) 76 (13) 77 (12) 75 (14) 0.758 
BMI categories (kg/m2) 
Normal (18.5 to < 25) 
Overweight (25 to <30) 
Obese (30 to <35) 





















Body Fat (%) 41 (5) 41 (6) 40 (4) 0.633 
Lean mass (kg) 42 (6) 42 (6) 42 (7) 0.997 
Postmenopausal (%) 65% 65% 67% 1.000 
Race (Caucasian, %) 91% 87% 100% 0.288 
Clinical Variables     
VO2peak (mL/kg/min) 21.4 (4.6) 20.9 (5.3) 22.4 (2.8) 0.326 
Time to Exertion (mm:ss) 9:54 (1:36) 9:41 (1:42) 10:21 (1:20) 0.186 
Peak Power (Watt) 123 (24) 120 (26) 130 (20) 0.180 
Relative Peak Power (Watt/kg) 1.6 (0.4) 1.6 (0.4) 1.8 (0.3) 0.214 
Heart Rate Max (bpm) 160 (17) 160 (20) 159 (12) 0.814 
Max RPE (Borg 6-20) 17 (2) 17 (2) 18 (1) 0.028 
Lactate (mmol) 6.8 (1.9) 6.4 (1.9) 7.6 (1.6) 0.030 
Six Minute Walk (m) 544 (67) 538 (72) 557 (53) 0.367 
Timed Up & Go (sec) 4.5 (1.2) 4.8 (1.2) 3.9 (0.7) 0.002 

















































Exercise attendance was similar between BCS and CTL groups with both groups 
attending approximately 71% of possible days of training (Table 3). Aerobic training 
prescription compliance differences between groups demonstrated a medium effect size (Cohen’s 
d= 0.63) but was not statistically significant (p=0.06). Strength training prescription compliance, 
was significantly different between groups, with controls completing more compliant days of 
strength training compared to survivors (CTL 18 (3) days vs. BCS 14 (5) days); Cohen’s d= 1.0, 
p=0.011) out of 48 total possible days. 
 











Intervention Attendance (days) 
Aerobic Compliance (days)  
Strength Compliance (days) 













There were no significant time x group interactions for VO2peak but a significant main 
effect for time was observed with both groups improving aerobic capacity by approximately 
1.2mL/kg/min (95% CI [0.15, 2.27]; p=0.03) from pre to post testing (Figure 2A). There was a 
significant time x group interaction for peak power (Figure 2B) with both groups demonstrating 
increased power but BCS increasing by approximately 10 more watts than CTL (95% CI 
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[1.8,17.5]; p=0.02) at post testing.  A significant main effect of time was observed for 6MWT 
with both groups walking approximately 35 meters more (95% CI [21.5, 49.1]; p<0.001) and for 
time to exhaustion (Figure 2C) with both groups completing almost a minute more of exercise 
during their peak test (95% CI [0.60, 1.29]; p<0.001) at post testing. Significant main effects of 
time and group were observed for TUG with both groups improving their time by approximately 
0.4 seconds (95% CI [-0.72, -0.17]; p<0.01) with a ~0.8 second difference between groups 
sustained after exercise training (95% CI [0.21, 1.5]; p=0.012). There were no significant time x 
condition interactions for VO2peak or significant main effects of time or group between BCS who 
had chemotherapy and those who did not (Table 5). 
 
Table 4 Results from linear mixed model of cardiorespiratory fitness outcomes after 16-weeks of 
community-based exercise training in breast cancer survivors and non-cancer controls 
  Mean (SD)     











39.8 (4.6) 0.04 0.901 0.651 0.668 
























137 (21.7) -0.76 0.020 0.493 <0.001 





















7.7 (2.0) -0.49 0.110 0.137 0.060 




594 (35) 0.08 0.798 0.295 <0.001 




3.6 (0.5) 0.27 0.399 0.012 0.003 
*adjusted for age. Data represented as means (SD). BCS, breast cancer survivors, n=31; CTL, controls, n 
=15; PWV, pulse wave velocity; BMI, body mass index; HR, heart rate; RPE, rating of perceived 




Figure 2 Aerobic capacity (A); Peak wattage (B); Time to Exhaustion (C) of BCS and CTL before 
and after 16-weeks of training. *P<0.05 from baseline; ^P<0.001 from baseline, #P<0.05 
interaction effect. Data for A are mean(SE) using estimated marginal means from adjusted model. 

















































Table 5 Results from linear mixed model of aerobic capacity after 16-weeks of community-
based exercise training in breast cancer survivors who did and did not receive chemotherapy 
  Mean (SE)    







BCS  + C 




22.0 (1.2) 0.713 0.940 0.070 
*adjusted for age. Data represented as means (SE) using estimated means from age-adjusted linear mixed 
model. BCS + C, breast cancer survivors who received chemotherapy, n=16; BCS - C, breast cancer 
survivors who did not receive chemotherapy, n =11 
 
 There were no significant associations found in univariate analysis between deltaVO2peak 




































Breast Cancer Survivors Controls
^ 
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Table 6 Independent associations of age-adjusted change in aerobic capacity (deltaVO2peak)^ with 









EOT 0.251 0.007 -0.024 0.006 0.205 
ATT^ 0.013 0.044 -0.118 0.203 0.591 
aCOMP^ 0.021 0.070 -0.057 0.197 0.268 
sCOMP^ 0.005 0.107 -0.137 0.352 0.377 
Footnote: EOT=Days since cancer treatment completion, ATT=days of attendance to exercise intervention, 
aCOMP=days of aerobic exercise compliance, sCOMP= days of strength exercise compliance   
^=higher values desired 
 
Table 7 Independent associations of age-adjusted change in aerobic capacity (deltaVO2peak)^ with 









ATT^ 0.045 0.008 -0.033 0.199 0.157 
aCOMP^ 0.059 0.082 -0.019 0.183 0.107 
sCOMP^ 0.030 0.121 -0.089 0.331 0.252 
Footnote: ATT=days of attendance to exercise intervention, aCOMP=days of aerobic exercise compliance, sCOMP= 
days of strength exercise compliance   
^=higher values desired 
 
Discussion 
Aerobic capacities of BCS are known to diminish during breast cancer treatment and 
survivorship as a result of “multiple hits” from therapy and lifestyle changes (L. W. Jones, 
Haykowsky, Swartz, et al., 2007). Survivors may experience up to 20-30% loss during their 
cancer journey but trial-based exercise interventions of similar length/design as our study have 
proven effective in improving aerobic capacity by 2.3 – 2.8mL/kg/min (Battaglini et al., 2014b; J 
M Scott et al., 2018).  As exercise intervention prescriptions have become more standardized 
(Campbell et al., 2019), it is important to determine if these prescriptions are still effective in 
improving aerobic capacity in real-world environments versus highly controlled lab settings.  
Breast cancer survivors in our study had aerobic capacities (pre: 20.9 (5.3) mL 
O2/kg/min, post: 22.2 (5.4) mL O2/kg/min) that approximated published norms for survivors who 
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are post treatment (21.5 mL O2/kg/min) (A. B. Peel et al., 2014). Aerobic capacities of our CTL 
participants were substantially lower than expected based on published norms from a meta-
analysis (Fitzgerald, Tanaka, Tran, & Seals, 1997). However, the values for our sedentary CTL’s 
are consistent with data on middle aged, sedentary women participating in other studies within 
our exercise lab in recent years and may potentially reflect a regional characteristic (Evans et al., 
2015; Wagoner, Hanson, et al., 2019). The 1.2 mL/kg/min improvement in aerobic capacity in 
both groups following training is only approximately a 6% improvement from baseline and in 
BCS, did not differ in BCS with regard to chemotherapy. Training interventions similar to GRH 
are generally expected to elicit up to a 15% improvement in aerobic capacity in healthy 
populations (Warburton, Nicol, & Bredin, 2006a, 2006b). The change observed in our study is 
less than what is considered clinically significant in non-cancer populations (Kodama et al., 
2009; Myers et al., 2002) and less than that observed in published meta-analyses where aerobic 
capacities of BCS increase by 2.3 – 2.5 mL/kg/min following training (Battaglini et al., 2014b; J 
M Scott et al., 2018). However, the improvements observed in our study are important as 
substantial cardiorespiratory fitness decline is a known manifestation of cancer survivorship and 
even small improvements can place survivors on a trajectory toward better health (L. W. Jones, 
Courneya, et al., 2012).  
Both physical (aerobic) capacity and functional capacity (6MWT, TUG) improved in 
both groups following exercise training at our community-based center. Our survivors functional 
capacity improvements in 6MWT and TUG performance reflect improvements typical for BCS 
(Swartz et al., 2017) but are still not equivalent to non-cancer population norms (Rikli & Jones, 
2013). Survivors and CTL groups also both increased the amount of time they could cycle on the 
bike at post-testing, indicating their stamina or ability to tolerate physical exertion for longer 
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time improved after exercise training. Collectively, these improvements support the benefits of 
modest exercise and have significant positive implications for tasks and demands of daily living. 
Potential rationale for these findings primarily revolves around elements of exercise 
engagement. While attendance/adherence in our study (71%) is similar to previously published 
exercise oncology studies (~70-75%) (K S Courneya et al., 2007; Amy A Kirkham et al., 2018), 
it is important to recognize that that engagement (purely in relation to number of days/week 
compared to guidelines) only reflects what would be approximately 2/3 of national exercise 
oncology guidelines (Campbell et al., 2019). Moreover, strength compliance (sCOMP) in our 
study was particularly poor.  It is logical to presume that improved exercise engagement closer to 
or matching recommended guidelines would lead to more or greater physiological changes. 
Difficulties with achieving exercise compliance, especially strength training, as observed in our 
study reflect the well-recognized challenges of exercise programming for clinical populations (K 
S Courneya et al., 2007; Kerry S Courneya et al., 2013; Amy A Kirkham et al., 2018; Neil-
Sztramko et al., 2019; van Waart et al., 2015)  
A limitation of our study but something that would help clarify our findings about the 
impact of the community-based training would be a third group of participants consisting of BCS 
who did not exercise for 16-weeks, or who completed prescriptions with differing levels of 
exercise volume (more days/reps/time) and/or differing intensity progression (higher vs lower 
intensity days). The CTL group in this study allowed us to compare exercise training equity 
between women who have been treated for cancer and women without a cancer/cancer treatment 
history, but does not provide insight to the natural fitness trajectory of BCS who do not exercise 
following treatment. When comparing absolute values of study outcomes between BCS and CTL 
groups, post-testing values for BCS tend to approximate pre-testing values for CTLs, as if they 
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are “catching up” to a more typical physical capacity profile of similarly-aged peers. 
Interestingly, improvements in peak power for BCS exceed the improvements in the CTL group, 
demonstrating a large effect size (Cohen’s d= -0.76). Peak lactate production also increases 
substantially in BCS from pre to post testing. Both of these changes result in post-testing values 
for BCS much like pre and post testing values for CTL and occur despite generally lower 
exercise compliance in the BCS group, but are positive nonetheless. It is unclear if these 
improvements in BCS are partially attributed simply to time since treatment completion plus 
exercise training, or if they truly respond differently to training stimuli than women without a 
cancer history. A third group of non-exercising BCS would very much improve the ability to 
compare natural versus training-induced changes. Other limitations to this study include 
relatively “self-selected” women who are mostly white, locally-residing, with the interest and 
job/family flexibility to be able to participate a 4-month training study. This likely does not 
reflect the majority of BCS. While it is well known that a survivor’s need to prioritize aspects of 
work, life and family balance around exercise participation can be a real challenge (Amy A 
Kirkham et al., 2018; Sweegers et al., 2018), future work would be improved by enrolling a more 
diverse pool of BCS for exercise training studies. 
For the future, community-based programs like the UNC Get REAL & Heel Program will 
be essential for accommodating the growing number and needs of survivors for guideline-
recommended exercise programs (Amy A Kirkham et al., 2018; Sweegers et al., 2019). While 
customization of exercise regimens as offered through the GRH program does not guarantee 
survivors will meet guidelines immediately, it may help facilitate the integration of exercise as a 
daily routine and is a first step to incorporating exercise as a life-long commitment. Furthermore, 
exercise facilities with proper programming and the capacity to customize both aerobic and 
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strength training may actually enhance or accelerate an individual’s capacity to reach guidelines 
prescriptions due to ability to provide variety in modes or type of exercise. It will be important to 
continue evaluation of similar community-based programs to insure survivors have the best 
prescription progressions and participation opportunities to improve their health.  
In conclusion, community-based exercise programs like the one used in our study show 
promise for improving both physical and functional capacity of BCS. Attention to strategies for 
improving both attendance and compliance to training protocols of increasing intensity, duration 
(aerobic training), and volume (strength training) will likely be important to maximize these 
outcomes. Providing cancer survivors with access to a physiologically beneficial and enjoyable 
exercise program like GRH cannot be overstated. Future efforts to create, operationalize, and 
continually evaluate community-focused exercise oncology programs has the potential to change 






CHAPTER SIX: RESEARCH SYNTHESIS 
 
Major Findings  
 
Collectively, the findings from this study support the effectiveness of UNC’s Get REAL 
& Heel community-based exercise program to improve physical and functional outcomes of 
women with early stage breast cancer when compared to age matched, non-cancer controls. 
From a research perspective, the findings provide critical physiological contributions to the 
exercise oncology arena and practical programming guides for the development of future 
interventions, studies, and facilities. However, from a humanistic point of view, these findings 
are not only positive, but almost celebratory. They provide long-awaited, scientifically-grounded 
confirmation that this program, which has operated for over a decade, can indeed provide the 
physical and functional benefits which survivors have consistently reported during participation, 
and for which the program was initially designed. The message of our data echoes the voices of 
GRH survivors. As a scientist and a physiologist, it is motivating to know we are able to provide 
those in need with an opportunity that can both feel and be beneficial. This critical component of 
our work and research is likely the most powerful take away, especially as it relates to 
dissemination and integration into standards of cancer care. The expansion and development of 
GRH type facilities to other locations will help provide more survivors with the opportunity to 
improve their health following a breast cancer diagnosis, but will require the support and 
approval of medical professionals. 
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Our breast cancer survivors clearly demonstrated impairments in aerobic capacity pre-
intervention (preVO2peak: 20.9 (5.3) which improved (postVO2peak: 22.2 (5.4)) following modest 
participation in the exercise intervention, but still do not approximate that of age-similar non-
cancer group norms.  Survivors were also able to cycle longer, produce more power, walk farther 
in 6-minutes, and became more agile in the timed up-and-go after training. The implication of 
these benefits translating into practical daily life tasks such as self and family care, grocery 
shopping, household chores, and daily stamina are of utmost importance in this population. The 
differences between exercise attendance and compliance were not surprising, as they have been 
previously recognized in published work, but further support the notion that individualized 
programming and consistent communication with patients about benefits of both strength and 
aerobic exercise is likely necessary to reach training targets. Furthermore, it is hard to evaluate 
the impact of national guidelines delivered through real world settings on survivor outcomes 
when survivors are not fully meeting those recommendations. 
In terms of aerobic capacity from a non-cancer perspective, a somewhat unexpected 
finding was the surprisingly low VO2peak values of our non-cancer controls, and lack of 
improvement following training. While we have observed similar values for similar participant 
profiles in other studies of our lab, the potential that this may be a regional effect or 
characteristic is intriguing and worthy of further investigation. Regional dietary and lifestyle 
habits potentially reflective of unique cultural characteristics may predispose particular groups of 
people to poorer cardiovascular fitness which is important to know and manage for their own 
outcomes. However, also being able to identify these trends across larger subsets of people of 
different locations is important from research perspectives because those subsets are commonly 
used as “healthy” comparison groups to clinical populations. The differences between clinical 
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and control groups, and between geographical sites may be substantially divergent. These 
regional tendencies or characteristics will be very important to evaluate and balance, especially 
from an external validity point of view. 
From a vascular outcomes perspective, our findings support the need for further 
investigation before conclusions can be confidently made. Between groups, arterial stiffness did 
not differ before or after exercise training. When groups were pooled for exploratory analysis, 
days of aerobic compliance appeared to benefit changes in arterial stiffness, suggesting exercise 
engagement may be a positive influence for vascular health. However, when exploring changes 
in the BCS group alone, arterial stiffness increased after exercise training in survivors treated 
with chemotherapy or radiation. The presence/absence and magnitude of change in arterial 
stiffness in patients primarily treated with non-anthracycline therapies is not currently known in 
the field. Therefore, it cannot be determined whether the observed increase in arterial stiffness of 
BCS in our study was potentially due to the effects of cancer therapies, was an increase 
potentially blunted by exercise, or was induced by exercise. It is imperative to determine these 
relationships especially as exercise is increasingly recommended for cancer survivorship. 
Patient-centered outcomes can absolutely be enhanced if we can better determine how to 
customize survivorship for women with different treatment histories.  
The scientific contribution of this work is substantial from the perspective that the 
growing number of cancer survivors will soon challenge the capacities medical clinics are 
capable of providing. If community-based settings can help benefit health outcomes of survivors 
and support ways to keep or improve their ability to be physically self-sufficient and 
independent, this may alleviate some of the stress and demand on medical providers allowing 
those professionals more time to manage more difficult or acutely concerning cases. The obvious 
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overall challenge is actually getting additional programs like GRH off the ground and supporting 
their services long term, as well as having survivors successfully engage in exercise for the long 
term. Furthermore, ensuring the trainers and staff of those facilities are properly prepared to 
work with the unique needs of survivors is critical for safety and efficacy. Leveraging existing 
exercise facilities and established local cancer support groups/networks can help spearhead these 
efforts. While likely an arduous process, these goals should not be pushed aside. 
Exploratory Findings 
 The exploratory analyses were significantly constrained by small sample size as they 
required participants having both useable PWV and VO2peak values pre and post testing. There 
were 26 BCS and 10 CTL included for exploratory analysis. As previously mentioned, PWV was 
not captured on some individuals due to physical architecture challenges around the neck 
preventing a clear pulse wave reading.  
The first exploratory analysis evaluated the relationship between pre-post change in 
aerobic capacity and baseline PWV, AIx, and Buckberg Index for each group. There were no 
significant associations found between deltaVO2peak and any of the baseline outcomes for either 
group. The second exploratory analysis repeated exploratory aim one but further minimized 
sample size as each group (BCS and CTL) were each separated into 2 groups: responder 
(deltaVO2peak ≥2.5mL/kg/min) or non-responder (deltaVO2peak <2.5mL/kg/min). No significant 
associations were found between deltaVO2peak and baseline outcomes for either response group 
in BCS or either response group in CTL. 
 The third exploratory analysis evaluated the relationship between baseline p16INK4a and 
deltaVO2peak and baseline PWV, 6MWT, and lean body mass in BCS (n=25). No significant 
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associations were found and, while still under investigation by other groups, the clinical utility of 
p16INK4a has not yet been determined. 
 
Strengths and Limitations 
The greatest strength of this study was the ability to evaluate the effectiveness of a long-
standing community-based program with a level of precision of an efficacy trial. Multiple gold-
standard, well-controlled, lab-based outcomes were evaluated over consecutive time points. 
Participants were also able to participate in a well-oiled training program run by veteran training 
staff. This highly experienced environment was a great strength for our study but indeed a 
difficult combination to replicate, at least at this time when other community-based settings are 
sparse. 
Significant limitations exist primarily regarding the population studied in this trial and an 
overall small sample size. Because of the 3-day/week training requirements, participants had to 
reside locally and/or have the interest and ability to travel to Chapel Hill three times per week. 
Overall, they also had to have the interest to exercise for four consecutive months. This made 
recruitment quite difficult and limited our sample size. Our population was a self-selected group 
which constrains the ability to extrapolate findings to women who may be less motivated or less 
able to attend sessions whether it be work, family, or transportation challenges among other 
things. For example, the majority of our participants were white, had decent flexibility around 
job demands (many retired or part time), and could manage family obligations which enabled 
them to participate in this study. We are well aware this profile is likely not the majority of 
women with breast cancer, especially those younger who may have more acute family and job 
demands. Improved race heterogeneity in a replica study would greatly benefit the capacity to 
evaluate training impact in a more representative population of breast cancer survivors. 
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Furthermore, if survivors are not motivated by involvement in a research trial, it may be quite 
difficult for survivors to prioritize exercise around other life-related challenges and exercise-
induced benefits may subsequently change. Collectively, these weaknesses support the need for 
effective programming strategies to provide community-based facilities with flexible hours and a 
supportive training team to accommodate and encourage the best engagement possible. 
Another limitation of our work revolves around the innate weakness of self-reported RPE 
as the gauge of exercise intensity in the training facility, however feasible and simple to use. 
Objective measures like heart rate can provide more specific, physiological based monitoring but 
can be challenging in a setting with limited number of trainers, and/or where smaller workout 
space may cause digital heart rate signals to overlap between participants and display incorrectly. 
However, exercise intensity is an important component to exercise progression. As our study 
suggests, specific health outcomes may be dependent on intensity engagement over time. 
Prescriptions are a known challenge when working with cancer survivors but using an RPE scale 
to monitor progression may be the most practical in our specific setting. Diligence to consistently 
re-contextualize patients to what the scale means and what represents their lowest and highest 
relative exertions can likely maximize the utility of this technique. 
Future Research 
From an outcome-specific perspective, a larger trial evaluating vascular health 
parameters at multiple time points in women treated with different types of chemotherapy and 
radiation regimens would be extremely helpful to profile the potential vascular threat of specific 
types and combinations of primary cancer treatment. Furthermore, evaluating the impact of 
exercise on these vascular profiles will help clarify is exercise is a safe and efficacious strategy 
to maintain or improve arterial health in BCS.  
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In conclusion, this study indeed supports the potential powerful role of community-based 
exercise training to benefit breast cancer survivors both physically and functionally, but more 
work is needed before concluding the impact of exercise on arterial health in BCS. More 
community-based programs are needed to serve the growing pool of survivors in general, and 
more programs that follow a consistent design reflective of ACSM exercise guidelines are 
essential to evaluate the efficacy of these national guidelines completed in a non-randomized 
controlled trial setting. Overall, the field faces the need for a volume of studies replicating the 
community-based design of our trial on physical and function outcomes and numerous studies to 
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